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ABSTRACT  
Hyperactivation of microglia is known to trigger the release of inflammatory mediators, 
which contribute to neurodegenerative disease progression and severity. Targeting of 
these immune mechanisms could lead to future therapeutic or preventive strategies 
for these diseases. Estrogens have been shown to improve the symptoms of 
neurodegenerative diseases by binding to estrogen receptors (ERs) and producing an 
anti-inflammatory effect by mainly reducing the release of pro-inflammatory cytokines 
like tumour necrosis factor alpha (TNFα), cytokine IL-6 and IL-1β. Nitric oxide (NO), 
prostaglandin E2 (PGE2) and their enzymes, the inducible nitric oxide synthase (iNOS) 
and ciclooxygenase-2 (COX-2), respectively, have also been shown to play a part in 
neuroinflammation. Isoflavones are phytoestrogens that have been known to display 
anti-inflammatory effects. Biochanin A (BCA) is an ERβ-selective isoflavone 
phytoestrogen found in red clover. Formononetin (FMN) is another phytoestrogen 
found in plant-derived red clover among others. In this research, two BCA and one 
FMN derivatives and a deoxybenzoin BCA intermediate have been synthesized. 
These derivatives were then evaluated for anti-inflammatory effect in 
lipopolysaccharide (LPS) activated BV2 cells microglia. BCA derivatives compound 1, 
2 and 3 were synthesized by producing a carbamate group, an esterification reaction 
and by following the synthesis route of deoxybenzoins, respectively. FMN derivative, 
compound 4, was synthesized by following the same rationale as for compound 1. 
Cultured BV2 cells were treated with BCA, FMN, compound 1, 2, 3 and 4 for 24 h after 
previous stimulation with LPS (100 ng/ml). Supernatants were collected and levels of 
NO, TNFα, IL-6, IL-1β and PGE2 were measured using ELISA. Further studies were 
carried out on compound 1 to determine its effects on protein levels COX-2 and iNOS 
by western blotting. Statistical analysis was performed using one-way ANOVA with 
post-hoc Student Newman-Keuls test. All compounds produced a significant and 
concentration dependent reduction in the production of NO. However, FMN, 
compound 1 and 4 reduced the release of TNFα and IL-6, while BCA only blocked 
TNFα and compound 2 not only did not show a significant reduction on TNFα but 
increased IL-6 production. BCA, FMN and compound 4 successfully decreased IL-1β 
and PGE2. Whilst compound 1 showed no effects and 2 augmented it. On the other 
hand, compound 1 slightly reduced iNOS and COX-2 expression. Compound 3 proved 
to be cytotoxic for BV2 cells. Our results suggest that the addition of a carbamate 
group (compound 1 and 4) to a natural precursor might be a better synthesis strategy 
than that of the attachment of an ester group (compound 2). Therefore, there is a need 
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for further investigation on the mechanism(s) of action of these compounds and their 
structure activity relationship in the light of the observed effects on pro-inflammatory 
mediators.  
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CHAPTER 1: GENERAL INTRODUCTION  
  
1.1 NEUROGLIA CELLS  
The concept of neuroglia, glial cells or merely glia, was introduced in 1858 by Rudolf 
Virchow who suggested the existence of a “connective substance, which forms in the 
brain, in the spinal cord, and in the higher sensory nerves a kind of Nervenkitt 
(neuroglia), in which the nervous system elements are embedded”. In other words, 
Virchow considered neuroglia an element that fills “space not occupied by neurones” 
that “also contains a certain number of cellular elements”. However, the second part of 
19th century was a golden age of cellular histology, and soon after initial findings, many 
different forms of glial cells were described. Conversely, after all these years, the 
function of glial cells in the nervous system is still not well understood (Verkhratsky and 
Butt, 2015).  
The term glia (from the Greek word meaning “glue”) reflects the nineteenth-century 
belief that these cells held the nervous system together somehow. The word still 
remains, despite the lack of any evidence that binding neurons together is among the 
many functions of glial cells. Glial roles that are actually well-established include 
maintaining the ionic milieu of nerve cells, modulating the rate of nerve signal 
propagation, modulating synaptic action by controlling the uptake of neurotransmitters, 
providing a scaffold for some aspects of neural development, and aiding in (or 
preventing, in some occasions) recovery from neural injury (Purves et al., 2001).   
Glia cells are a far cry from neurons. That is so, that glial do not participate directly in 
the synaptic process meaning they cannot send electrical signals as such but instead, 
they support neurons during this task (Purves et al., 2001). The more recent definition 
is based on the systemic function of all neuroglia cells and defines neuroglia as 
“nonneuronal cells residing in the brain responsible for the homeostatic maintenance 
of the nervous system, represented by highly heterogeneous cellular populations of 
different origin, structure, and function” (Verkhratsky and Butt, 2013).   
Neuroglia in the mammalian nervous system is divided into the central nervous system 
(CNS) glia and peripheral nervous system (PNS) glia. Microglia are glial derived from 
hematopoietic stem cells in mesodermal tissue within the CNS. They share many 
characteristics with macrophages from the periphery since they derive from monocytes 
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precursors. Hence, their main function is to remove cellular debris from sites of injury 
and to initiate an immune response (Purves et al., 2001).  
1.2 ROLE OF MICROGLIA CELLS IN NEUROINFLAMMATION  
1.2.1 Overview  
It is widely assumed that the CNS is an immune-privileged tissue, suggesting that any 
antigen or strange organism entering the brain and spinal cord do not initiate an 
immune response. While this idea has been hypothesized over the last 70 years, it is 
clear that immune privilege is not unconditional since immune responses do take place 
in the CNS and are vital for both modelling the brain during development and controlling 
infections in the brain. However, it is undeniable that the brain is much better protected 
than other organs given the presence of the blood brain barrier (BBB) and any type of 
cell or strange body cannot just enter at their will. Nonetheless, when the BBB is 
compromised, it is unable to control such selection, thus contributing to the tissue 
damage (Woodroofe and Amor, 2013). Besides the presence of this gatekeeper, there 
are specific cells responsible for initiating an immune response at this level, that is 
microglia cells.  
Microglia are one of the glia cell types known as the brain immune cells acting as 
specialized macrophages capable of phagocytosis that protect neurons of the central 
nervous system. They can either phagocyte dead neurons or assist them after brain 
tissue injury. To accomplish its function, microglia cell undergoes dynamic changes on 
its structure. Microglia also participate in the physiology of the nervous system through 
regulation of development and connectivity of neural networks, combining thus, a 
defensive role with homeostatic and neuroprotective functions (Verkhratsky and Butt, 
2015).  
Nevertheless, for the major part of a century, the function of microglia in the CNS was 
a topic of controversy. Originally identified by Franz Nissl in 1899 as ‘Stabchenzellen’ 
or rod-like cells and further classified by Pío del Río Hortega in 1919, these cells were 
described as non-neuronal and non-astrocytic population. Furthermore, Hortega’s 
observation suggested a capacity for phagocytosis, indicating that these cells were 
more than just space filler or connective cells between neurons, a breakthrough that 
was not accepted until 60 years later, not even by Hortega’s mentor, Ramon y Cajal, 
who urged Hortega not to publish. Thus, it was not until the early 1980s, when the 
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development of new technologies and ideas began to reveal the true nature of microglia 
as the brain’s resident immune cells giving Hortega the credit he deserved (Cherry et 
al., 2014).   
1.2.2 Microglia distribution and morphology  
Microglial cells are mesodermal in origin but their precursors are not simply blood 
macrophages, but rather derive from primitive myeloid progenitors that originate from 
the extraembryonic yolk sac (Verkhratsky and Butt, 2015).   
Microglia are well-organised in the brain and are homogeneously distributed throughout 
the CNS, with more or less similar densities in different regions. The microglial cells in 
the healthy CNS have small cell bodies from which several main processes are 
extending. Every cell has its own territory, about 15-30 µm diameter, so rare is the 
occasion in which microglia’s processes overlap.   
As resting microglia, these cells are the 
fastest moving cells in the brain. Their 
processes are continuously scanning their 
territory in search of any anomaly; this is 
a fairly rapid movement with a speed of 
nearly 1.5 µm/min and thus microglial 
processes represent the fastest moving 
structures in the brain. At the same time, 
microglial processes also constantly send 
out and retract small protrusions, which 
can grow and contract by 2–3 µm/min. 
Considering the velocity of these 
movements, the parenchyma of the brain 
can be completely scanned by microglial 
processes every several hours (Figure 1). 
Such sophisticated system, endows the 
CNS with the ability of immediately 
respond to CNS damage and a 
pathological event, in which resting 
microglia become activated undergoing a morphological transformation from resting 
cells to amoeboid-like morphology which gain more motility and act as tissue 
a )  
b )  
Figure 1. Microglia mobility. a) Microglia 
processes in health tissue scanning its 
territory. b) Microglia responding to injury 
by addressing its processes to the site of 
insult (Verkhratsky and Butt, 2013). 
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macrophages (Figure 2). These activated cells have the capacity to migrate, proliferate 
and phagocytise.  During this transition, resting microglia retract their processes, which 
become fewer and much thicker, increase the size of their cell bodies acquiring an 
amoeboid-like shape, change the expression of various pro-inflammatory enzymes and 
receptors and begin to produce immune response molecules such as cytokines (CKs) 
triggering a state of acute neuroinflammation (Verkhratsky and Butt, 2013).   
  
Figure 2. Time-lapse imaging of microglia cells. a) Inactivated microglia cells with 
highly ramified branches. b) Activated microglia possess an enlarged cell body with 
shorter branches (Dailey, n.d.).  
1.2.3 The two faces of microglial cells in neuroinflammation  
Within the CNS, inflammation and innate immunity are believed to contribute to the 
pathogenesis and neurodegeneration that occur in several diseases and conditions. In 
the context of neuroinflammation, research had been focusing on the roles of innate 
immune cells (macrophages, dendritic cells and granulocytes) of the periphery and 
which are capable of egress in the brain. However, bias has changed in order to study 
the roles of CNS resident cells, including astrocytes and microglia. In the subsequent 
sections of this chapter, we will discuss the emerging roles of CNS microglia resident 
cells.  
1.2.3.1 Defining neuroinflammation  
Inflammation is a complex phenomenon within the body triggered by mechanical, 
chemical or biological factors. The characteristics of any of these factors along with the 
time of exposure to them determine the type of inflammatory response generated: 
acute or chronic. Acute inflammation may be beneficial as a mean to restore the 
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homeostasis at the place of injury. Problem arises when the source of the stimuli is 
permanent in a way that the immune system enters in a vicious cycle and a state of 
chronic inflammation is established. In the central nervous system (brain and spinal 
cord) that state is termed as neuroinflammation.   
Unresolved neuroinflammation generally leads to chronic neurodegenerative diseases, 
which are commonly characterized by the decline of cognitive functions. These include 
Alzheimer’s disease, Multiple Sclerosis, Parkinson’s disease and other dementias. Due 
to the implication of neuroinflammation in such kind of diseases, the regulation of 
inflammation in the CNS is one of the relevant processes involved in the pathogenesis 
of neurodegenerative disorders. Immune activation in the CNS always involves the 
innate immunity activation as a first step and, therefore, the activation of microglia and 
astrocytes cells, which in normal conditions are in charge of the regulation of 
homeostasis of the brain tissue. Although peripheral immune cells are also important 
to spread the inflammatory signals within the CNS.   
1.2.3.2 Role of microglia cells and its parallelism with macrophages  
Both in vitro and in situ studies of peripheral macrophages have demonstrated that 
macrophages have different phenotypes meaning that they can vary with respect to 
their activation state. As a result, macrophages can contribute to either pro or 
antiinflammatory processes (Woodroofe and Amor, 2013). The phenotype activated will 
depend on the “microenvironment” created by cytokines released by the immune cells, 
which will lead the polarization of the immune response.  
In agreement with Hortega’s original description, microglia have been classically 
described to exist in two states or phenotypes, resting and activated (Cherry et al., 
2014). However, due to its nature as immune cells, microglia are never truly ‘resting’ 
but constantly scanning around them for new threats in efforts to maintain homeostasis. 
Therefore, as the ‘resting’ term is not accurate neither it is considering the ‘activated’ 
state as a single state. In fact, the term ‘activation’ is an oversimplification of a range of 
different activated states.   
So far, two major activated microglia states have been described. The first is classical 
activation, in which microglia cells produce a pro-inflammatory response, while the 
second is referred to as alternative activation in which microglia promotes an 
antiinflammatory phenotype involved in damage repair and debris clearance (Figure 3) 
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(Cherry et al., 2014; Colton, 2009).  Nonetheless, all phenotypes have in common that 
they work to support and protect the structural and functional integrity of the CNS 
(Verkhratsky and Butt, 2013).    
 
  
  
  
  
 
 
Figure 3. Polarization of microglia. M1 polarization (classical activation) can be 
accomplished in the presence of pro-inflammatory mediators whereas M2 polarization 
(alternative activation) is commonly achieved through the addition of IL-4 or IL-13 
(adapted from Woodroofe and Amor, 2013).   
1.2.3.3 Classical activation: M1 cells  
Microglia cells, as macrophages in the periphery and other immune cells, have the 
ability of identifying exogenous molecules triggering the release of cytokines, among 
others. Cytokines function as immune messengers between cells to promote the 
classical activation state. The classical activation state has classically termed as M1 
cells and this term is equivalent to the Th1/2 terminology used for T cells in the 
periphery. By these means, microglia cells manage to promote the pro-inflammatory 
responses required to clear the infection or to boost the adaptive immune response 
(Woodroofe and Amor, 2013).   
The functional effects of classical activation are geared towards antigen (Ag) 
presentation and the killing of intracellular pathogens. Therefore, many immune 
receptors and enzymes are upregulated in order to serve that purpose. Once a ligand 
binds any of the wide range of immune receptors expressed on microglia cells, an 
overall upregulation of costimulatory molecules as well as the major histocompatibility 
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complex II (MHC II) is induced to allow for Ag-presenting activity of microglia and 
increased crosstalk within other immune cells (Cherry et al., 2014). M1 cells also 
upregulate levels of some Toll-like receptors (TLRs), several cell surface and 
intracellular molecules (CD14, CD11b, CD45, CD68) and matrix metalloproteinases 
(MMPs). With respect to cytokine production, M1 cells secrete pro-inflammatory 
cytokines, including interleukin (IL) such as IL-1β, IL-6, IL-12, IL-23 and tumor necrosis 
factor alpha (TNF-α). Especially, TNFα and IL-1β have been demonstrated to have an 
important role in the development of CNS inflammation through the disturbance of 
BBB, which further facilitates the infiltration of peripheral immune cells enhancing the 
inflammation process (Lei et al., 2015). In addition to cytokines, several chemokines 
and other effector molecules are produced (Woodroofe and Amor, 2013) as well as 
reactive oxygen species (ROS). It is worth mentioning that one of the most important 
ROS is nitric oxide (NO) which is released by a key microglia enzyme, the inducible 
nitric oxide synthase (iNOS) (Cherry et al., 2014).   
Prostaglandins (PGs) are another group of molecules very present during 
inflammatory processes and it is a major element during chronic inflammation and 
cancer (Kalinski, 2012). PGE2 affects microglial activation including migration, 
phagocytosis, and production of cytokines and nitric oxide (Nagano et al., 2016). Being 
by-products of arachidonic acid, produced by cyclooxygenases (constitutively active 
COX-1 and inducible COX-2) and prostaglandin synthases, they are characterised by 
their lipid structure formed by 20 carbons and a pentane. PGE2 is the main product of 
COX-2 and its presence requires a rigorous balance between COX-2 and 
15hydroxyprostaglandin dehydrogenase (15-PGDH), an enzyme responsible for 
driving PGE2 degradation process (Kalinski, 2012). Concentrations of the pro-
inflammatory PGE2 has proved to be elevated in patients suffering from 
neurodegenerative diseases having its effect on glial cells since PGE2 receptors are 
expressed in their surface, however, they are not specific of these cells. In fact, 
neurons express such receptors to a higher extent than other cells in the brain (Zhu et 
al., 2005). This situation makes harder to identify the exact role of PGE2 in 
neuroinflammation.   
All in all, the ratio of particular cytokines has been used to identify inflammatory 
microglia. For example, it was suggested that IL-12 high, IL-10 low production is a 
simple way to distinguish inflammatory cells (Mantovani et al, 2004). However, due to 
the plastic nature of microglia cells, classifying this cells in vivo is not easy practice.   
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1.2.3.4 Alternative activation: M2 cells  
In contrast with pro-inflammatory M1 cells, alternatively activated microglia cells 
socalled M2 cells, express cytokines and receptors that are implicated in inhibiting 
inflammation and restoring homeostasis once the risk of infection or damage has been 
dealt with. Examples of anti-inflammatory cytokines are IL-10, TGF-β and IL-1 receptor 
antagonist (IL-1Ra). IL-10 exerts the opposite effects to those caused by 
proinflammatories cytokines, through modulation of the latest, chemokines and 
oxidative species in microglia (Lei et al., 2015). Consequently, it appears that when 
there is a lack of M2 cell differentiation in the CNS, problems can arise.   
As M2 macrophages, M2 microglia are characterized by their enhanced ability to 
phagocytise and secrete anti-inflammatory and neurotrophic factors that can promote 
repair. Within M2 phenotype, diverse subsets can be identified. However, their 
characterization by markers is not easy matter since not many are well established. 
Interestingly, there are two enzymes, which despite their opposite function, can be two 
powerful markers. Such enzymes are the inducible nitric oxide synthase (iNOS) and 
the enzyme arginase 1 (Arg1). Ironically, by using arginine, which is the same 
substrate used by iNOS, Arg1 can effectively compete with iNOS to downregulate 
production of NO. Despite the benefit of having specific markers, using just one or two 
is limiting and ignores the overall diversity of M2 phenotypes (Cherry et al., 2014; 
Corraliza et al., 1995).  
Therefore, and due to their nature, another way to classify the function and phenotype 
of M2 cells is based on the cytokines that induce them. In this sense, three subtypes 
have been identified depending on what cause their alternative activation and classify 
as ‘M2a’, ‘M2b’ and ‘M2c’ (Table 1).   
An important consideration regarding M2 phenotypes is that these states were typically 
elucidated in vitro following exposure to a few stimuli. This does not represent the 
complex environment given in tissue. Moreover, such detailed classification has been 
primarily observed in the periphery. Therefore, there is a controversy whether this 
classification should be applied or not to the brain resident microglial cells.   
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Table 1. Different subtypes for M2 microglial cells: M2a, M2b and M2c. (IL: 
interleukin, TLR: toll-like receptor, NF-kB: nuclear factor kappa-light-chain-enhancer 
of activated B cells, Arg1: argenine 1, TGF-β: Transforming growth factor beta).  
M2 
Subtype  
Activating 
factor  
Comments  
M2a 
IL-4 
IL-13 
Their main function appears to be suppression of 
inflammation. Upon activation by IL-4 and IL-13 
through IL-4Rα, a downstream process that lead 
to potent anti-inflammatory functions is induced 
(inhibition of NF-ĸB, Arg1 upregulation, 
production of scavenger receptors for 
phagocytosis) (Gadani et al., 2012).   
  
M2c  
IL-10 
glucocorticoids  
TGF-β  
Appear to be involved in tissue remodelling after 
inflammation has been controlled (Cherry et al., 
2014).  
  
M2b  
  
TLR  
No specific markers for M2 have been found for 
this subset. However, they do express the typical 
IL-10 high, IL-12 low M2 cytokine profile 
(Mantovani et al., 2004).   
  
1.3 TOLL-LIKE RECEPTORS IN NEURODEGENERATION  
While the CNS was once considered an immune-privileged site, it is now recognized 
that both infiltrating and CNS resident cells actively participate in several aspects of 
innate immunity and are important for maintaining neural function (Hansson and 
Edfeldt, 2005). Particularly, microglia and astrocytes are the innate immune cells 
responsible for maintaining the homeostasis in the brain whenever a threat, either 
exogenous or endogenous, disturbs the biological balance. These cells do not act on 
their own but also recruit and activate cells that participate in the adaptive immunity. 
As such, they display a series of inflammatory mediators, which in turn, may also 
increase the expression of Toll-like receptors (TLRs) in the CNS cells. Therefore, the 
role of TLRs in neurodegenerative diseases has been under study, for example, in 
Alzheimer’s disease (AD) where the absence of acute inflammation but persistent glial 
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activation is observed and, in Multiple Sclerosis (MD) where an adaptive immune 
response is provoked following glial stimulation and inflammation (Popovich et al., 
2008).   
Taken all together, in the subsequent sections of this chapter, an overview of the innate 
immune system focusing on TLRs and more specifically on the Toll-like receptor 4 
(TLR-4) activation and the signalling pathways for which is responsible and its role in 
neuroinflammation by modulating microglial cells will be given.  
1.3.1 Overview of toll-like receptors activation and signalling  
Prior to activating the adaptive immune response, cells of the innate immune system 
first respond to pathogens, or danger signals, within their environment. Innate immune 
cells such as dendritic cells, macrophages and monocytes in the periphery and, 
astrocytes and microglia cells in the CNS, all possess both surface and intracellular 
receptors capable of recognizing pathogen-associated molecular patterns (PAMPs) 
and damageassociated molecular patterns (DAMPs) (Woodroofe and Amor, 2013; 
Suzumura and Ikenaka, 2013). Some examples of PAMPs are lipopolysaccharide 
(LPS), peptidoglycan, lipoteichoic acids and mannans, which are widely expressed by 
bacteria but are not present on host tissues. They are recognized by the pattern 
recognition receptors (PRRs) of the innate immune cells to distinguish pathogens from 
self-antigens. Amongst the large number of different PRRs are the Toll-like receptors, 
which are the best known group of innate immune receptors (Woodroofe and Amor, 
2013; Cherry et al., 2014).   
The toll gene was originally identified by Christiane Nüsslein-Volhard, Eric Wieschaus 
and colleagues in the fruit fly Drosophila melanogaster in 1985 (Hansson and Edfeldt, 
2005). In accordance with the Drosophilia receptor, mammalian TLRs are expressed 
by cells of the innate immune system being specific for different components of 
microbes (Delves et al., 2011; Lu et al., 2008).   
Different cell types express TLRs in the brain (Table 2). They are not, however, always 
expressed at the same extent. For instance, TLRs are barely expressed in astrocytes 
in normal conditions, but when the situation changes and an inflammatory process 
begins, higher levels of TLRs are detected on their surface (Bsibsi et al., 2002). TLRs 
are also expressed in microglia cells, which represent the first line of innate defense 
against viral and bacterial infection of the CNS. These cells respond to TLR stimulation 
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by producing cytokines and other inflammatory mediators and by enhancing 
phagocytosis of microorganisms and aggregated extracellular proteins. So much so 
that, microglia express all TLRs expressed in humans (Table 2).   
Table 2. Toll-like receptor expression in the central nervous system. TLR: Tolllike 
receptor; LPS: lipopolisacharide (Woodroofe and Amor, 2013).  
  
  
TLR  
  
  
LIGAND  
    
CELL TYPE  
 
  
  
Neuron  
  
Astrocyte  
  
Oligodendrocyte  
  
Microglia  
Brain 
Endothelium  
TLR1  Tryacylated 
lipoproteins  
  
  
  
✓  
    
✓  
  
TLR2  Glycolipids, 
lipoproteins  
    
✓  
  
✓  
  
✓  
  
✓  
TLR3  dsRNA  ✓  ✓  ✓  ✓  ✓  
TLR4  LPS    ✓    ✓  ✓  
TLR 5  Flagellin    ✓    ✓  ✓  
TLR6  Diacylated 
lipoproteins  
        
✓  
  
✓  
TLR7  ssRNA  ✓      ✓  ✓  
TLR8  ssRNA  ✓      ✓  ✓  
TLR9  Unmethylate 
d CpG-DNA  
  
✓  
  
✓  
    
✓  
  
Pathogen components such as LPS can readily induce the activation of microglia cell. 
TLR4 signalling has been well established in the pathologies of neuroinflammation. 
Two rather important transcription factors activated by TLR signals are NF-κB, which 
promotes the expression of various cytokines and endothelial adhesion molecules; the 
interferon response factor 3 (IRF3), which stimulates the production of type I 
interferons, cytokines that block viral replication during an antiviral response (Figure 
26  
  
 
4) (Delves et al., 2011); and the p38 MAPK (mitogen-activated protein kinase) which 
also has essential roles in inflammation, apoptosis, cell cycle and differentiation (see 
review: Zarubin and Han, 2005).  They also induce the activation of COX-2 and iNOS 
enzymes, which are essential to induce potent immune responses (Lei et al., 2015). 
Indeed, nitric oxide (NO) production, mediated by the iNOS enzyme, has been 
extensively associated to neuroinflammation and neurodegenerative processes 
(Morales et al., 2014). For instance, in patients with AD, increased production of iNOS 
causes post-translational modifications instigated by NO, resulting in the increment of 
Aβ peptide aggregation in the amyloid plaques (Butterfi et al., 2007; Kummer et al., 
2011). In addition, epidemiological studies advocate that COX inhibitors reduce the 
risk of AD and PD (Krause and Muller, 2010).  
  
Figure 4. Ligands and activation pathways of TLRs. Different microbial antigens 
join to and stimulate different TLRs. These several TLRs, expressed either at the cell 
surface or in endosomes, activate similar signalling mechanisms, which provoke 
innate immune responses. Other receptors, such as those for viral RNA or bacterial 
peptides are found in the cytoplasm.  (IFN, interferon; IRF-3, interferon response factor 
3; LPS, lipopolysaccharide; NF- κB, nuclear factor κB; TNF, tumor necrosis factor; 
MCP-1, monocyte chemoattractant protein 1) (Abbas et al., 2014).   
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Within the wide spectrum of TLRs, in particular, TLR4 has shown to be highly 
expressed on microglia mediating neuroinflammatory diseases. Numerous studies 
have demonstrated TLR4-dependent activation of microglia in neurodegenerative 
diseases such as AD and PD (Yao et al., 2013; Lehnardt et al., 2003). LPS is one of 
the best studied bacteria endotoxines that could eventually cause systemic 
inflammation and sepsis through TLR4 if the inflammatory response is amplified and 
uncontrolled.   
Upon LPS recognition, TLR4 undergoes dimerization and recruits its downstream 
adaptors. Such adaptor proteins are MyD88 (myeloid differentiation primary response 
gene 88), TIRAP (TIR domain-containing adaptor protein, also known as Mal, 
MyD88adapter-like), TRIF (TIR domain-containing adaptor inducing IFN-b), TRAM 
(TRIFrelated adaptor molecule), and SARM (sterile and HEAT-Armadillo motifs-
containing protein). Different TLRs use different combinations of adaptor proteins 
allowing a differential downstream signalling. Interestingly, TLR4 is the only known 
TLR which utilizes all these adaptor proteins through the MyD88-dependent pathway.  
MyD88-dependent pathway (Figure 5) was shown to be responsible for 
proinflammatory cytokine expression by recruiting and sequentially activating a set of 
adaptors proteins which in turn activate two different kinase enzymes, that is IKK (IkB 
kinase) and MAPK (mitogen-activated protein kinase). The activation of these kinases 
drives a rapid phosphorylation and release of two major transcription factors protein 
complexes: NF-kB and AP-1 respectively. Both transcription factors have an important 
role in the expression of pro-inflammatory cytokines. It should be noted that, NF-kB 
and AP-1 phosphorylation is still induced in the MyD88-deficient macrophages 
suggesting that they can also be activated through a MyD88-independent pathway (Lu 
et al., 2008).  
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Figure 5. Scheme of the MyD88-dependent pathway activated upon TLR-4 
dimerization. The purpose of this signal is to activate two main pro-inflammatory 
pathways: the IKK protein complex which allows the NF-kB transcription factor to enter 
into the nucleus, and the MAPK leading to the induction of the AP-1 transcription factor 
(Lu et al., 2008).  
1.3.2 Toll-like receptors and microglia in neurodegenerative diseases  
As stated before, TLRs are narrowly related to pro-inflammatory mediators’ release 
and vice versa. Therefore, their function has been associated with several 
neurodegenerative diseases.   
Many studies have considered the way TLRs may affect, for instance, Alzheimer’s 
disease. As the most common cause of dementia in human characterized by 
progressive neurodegeneration, a lot of attention has been drawn to this disease to be 
studied from many angles. It is widely known that AD is characterized by the 
extracellular accumulation of amyloid beta peptides (Aβ) in neuritic plaques and the 
intercellular aggregation of hyperphosphorylated tau protein in neurofibrillary tangles. 
In addition to these pathological hallmarks, inflammation orchestrated by the innate 
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immune system is observed in the brain of AD patients (Akiyama et al., 2000). That is 
because Aβ exerts a direct action on neurons but also an indirect pro-inflammatory 
action through microglia cells to produce neurotoxicity promoting neurodegeneration 
(for reviews see: Yu and Ye, 2015; Heneka et al., 2015). Aβ42 has been reported to 
interact with microglial cells through several reported cell surface receptors and here 
is where TLRs take part in the development of neuroinflammation. Aβ recognition has 
been reported to be mediated by microglial cells TLRs through the interaction with 
other cell surface receptors to initiate the activation of intracellular signalling pathways.  
As seen in section 1.3.1, TLRs activated by any of its ligands, in this case Aβ, would 
lead in the production of pro-inflammatory cytokines and reactive oxygen and nitrogen 
radicals contributing to the inflammatory response and neuronal toxicity. However, 
TLRs along with CD14 have been implicated in the phagocytosis of Aβ addressed by 
microglia (Liu et al., 2012). Despite the latest beneficial role of microglia, apparently, 
as the disease progresses, this ability to phagocyte the accumulation of Aβ decreases 
due to a reduction on the expression of Aβ-degrading enzymes, therefore, promoting 
the production of pro-inflammatory modulators (for reviews see: Yu and Ye, 2015; 
Arroyo et al., 2011).   
MS is another chronic neurodegenerative disease characterized by the 
demyelinatation of neurons due to neuroinflammatory processes that involves 
activated lymphocytes, macrophages and resident glial cells (astrocytes and microglia) 
in the brain, although the etiology is not completely clear. As for AD, TLRs and 
microglia have also been associated to this over-inflammatory processes in MS (see 
Arroyo et al., 2011).   
1.3.3 The Rel/NF-κB signal transduction pathway  
Rel or NF-κB (nuclear factor kappa-light-chains-enhancer of activated B cells) complex 
was first discovered in B cells and described as a nuclear factor that bound to κB DNA 
sites (Chen et al., 1999). There are numerous evidences that indicate that the major 
signal pathway involved in the onset and amplification of the inflammatory response is 
that which affects to the NF-κB activation. These proteins comprise one of the most 
ubiquitous family of transcription factors that are involved in the control of several 
cellular processes, such as immune and inflammatory responses (since light chains 
kappa are immunoglobulin crucial components), cell development, cellular 
proliferation, and apoptosis. Hence, uncontrolled deregulation of NF-κB by any 
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pathological situation, is related to inflammatory and autoimmune diseases as well as 
cancer (Gilmore, 2006).   
From a structural point of view, Rel/NF-κB is an ensemble of protein dimers that share 
a common N-terminal domain of 300 amino acids that controls DNA transcription. The 
N-terminal is a highly conserved DNA-binding/dimerization domain (DBD) so-called 
the Rel homology (RH) domain (Figure 6). RH domain mediates either heter- or 
homodimerization which is required for the transcription factor to bind to the DNA target 
site. Different dimers possess distinct transcriptional functions on the grounds of that 
they directly bind to enhancer sequences of distinct genes (Chen et al., 1999). NF-kB 
dimers are originated from the combination of five different proteins: p105 or p50, p100 
or p52, RelA or p65, RelB, c-Rel from which only the last three can directly activate 
the transcription of target genes (Table 3) (Phelps et al., 2000). The p50-p65 
heterodimer is the most abundant form of NF-κB dimers (Chen et al., 1999).    
Rel/NF-κB proteins can be divided into two classes based on the presence or absence 
of an activation domain (Phelps et al., 2000) located in the C-terminal domain to the 
RH domain:   
- Members of class one (NF-κB proteins p105, p100) have long C-terminal 
domains that contain multiple copies of ankyrin repeats, which act as 
transcriptional repressors. This domain is known as TRD (transrepression 
domain). However, p105 and p100 are not active by themselves but they need 
to be split into shorter sequences by either proteolysis or arrested translation to 
p50 and p52 respectively. As such, these first class members are usually not 
activators of transcription but repressors, however they can induce gene 
expression when forming dimers with members of the second class of Rel/NFκB 
transcription factors.   
- The second class (the Rel proteins) includes c-Rel (and its retroviral 
homologue v-Rel), RelB, RelA (p65). This second class of Rel proteins contains 
a C-terminal transcriptional activation domain (TAD), which enables gene 
expression. Hence, Class II NF-ĸB promotes gene expression being 
downregulated by Class I.   
The NF-κB active and functional is captured in the cytosol forming an inactive complex 
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due to its binding to NF-ĸB inhibitors (IĸBα, IĸBβ, IĸBε, IĸBƳ, IĸBζ and Bcl-3) in resting 
cells (Phelps et al., 2000). Therefore, NF-ĸB belongs to the category of "rapid-acting" 
transcription factors meaning it does not required a synthesis of novo (other members 
of this family include transcription factors such as c-Jun, STATs, and nuclear hormone 
receptors) (Bonizzi and Karin, 2004).  
 
 
 
 
Figure 6. Diagram of NF-κB protein structure. Structurally speaking, two classes of 
NF-κB proteins can be differentiated: class I and class II. Both contain a N-terminal 
DNA-binding domain (DBD) and a C-terminal fragment. The latter determines the 
protein function. Whilst class I proteins contain ankyrin repeats endowed with 
transrepression activity (TRD), class II proteins are formed by a transactivation domain 
(TAD) which activates the transcription of target genes (Wikipedia contributors, n.d.).  
Table 3. Five members of NF-ĸB (nuclear factor kappa-light-chains-enhancer of activated B 
cells) family in mammals.  
CLASS  PROTEIN  ALIAS  GEN  
 Class I  
NF-κB1  p105  p50  NFκB1  
NF-κB2  p100  p52  NFκB2  
Class II  
RELA  p65  RELA  
RELB    RELB  
c-REL    REL  
Three different NF-κB activation pathways have been described, the classical or 
canonical pathway (Figure 7), the alternative or non-canonical pathway and the third 
atypical pathway which is induced by agents that damage the DNA such as reactive 
oxygen species or ultraviolet radiation. Nonetheless, the most frequent pathway 
observed is the classical, which is activated in response to various inflammatory 
stimuli. The TNFα, IL-1β, lymphocyte T receptor (TCR) and many bacterial products 
such as LPS are solely a few examples of molecules that lead to NF-κB activation and 
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rapid changes in gene expression (Bonizzi and Karin, 2004). Since the methodology 
followed in this work in order to induce an inflammatory response by BV2 microglia 
cells involves activation by LPS, only the classical pathway is deeply described below.  
Classical or canonical pathway  
As recently mentioned, in unstimulated cells, the NF-κB dimers are sequestered in the 
cytoplasm by a family of inhibitors, called IκBs (Inhibitor of κB). Although the IκB family 
consists of IκBα, IκBβ, IκBε, and Bcl-3, the best-studied and major IκB protein is IκBα. 
Because of the presence of ankyrin repeats in their C-terminal halves, p105 and p100 
also function as IκB proteins.  
In the activation of the classical pathway by LPS, firstly LPS binds to its binding protein 
(LBP) present in the blood. The complex LPS/LBP is combined with TLR-4 in such a 
way that sequentially activates various kinases, among them the NF-κB inducing 
kinase (NIK) and the IκB kinase (IKK). IKK is composed of a heterodimer of the 
catalytic IKKα and IKKβ subunits and a regulatory protein termed NEMO (NF-κB 
essential modulator) or IKKϒ, being IKKβ the predominant in this pathway. The 
activation of this kinase leads to the phosphorylation of IκBα in two serine residues 
(Ser32, Ser36) located in an IκB regulatory domain. When phosphorylated on these 
serines, the IκB inhibitor molecules are modified by a process called ubiquitination, 
followed by a subsequent degradation by the proteasome 26S (Figure 7) releasing 
then the NF-κB.  
With the degradation of IκB, the NF-κB complex is then free to enter the nucleus where 
it can promote the expression of specific genes that have DNA-binding sites for NFκB 
nearby. NF-κB transcription factors bind to 9-10 base pair DNA sites (called κB sites) 
as dimers. In general, the genes that are regulated by NF-κB can be classified in four 
groups: genes that code for inflammatory and immunomodulatory proteins, genes that 
regulated the cell cycle, antiapoptotic genes and those which encode negative 
regulators for NF-κB. NF-κB turns on expression of its own repressor, IκBα.  
The newly synthesized IκBα can enter the nucleus, remove NF-kB from DNA, and 
export the complex back to the cytoplasm to restore the original latent state, thus, 
forming an auto feedback loop, which results in oscillating levels of NF-κB activity.   
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In light of the stated above, the activation of the NF-κB pathway is generally a transient 
process, lasting from 30-60 minutes in most cells (Gilmore, 2006; Lawrence, 2009).  
 
Figure 7. The NF-κB classical pathway. NF-κB (p50-p65 heterodimer in the figure) 
is placed in the cytosol forming a complex with the inhibitory protein IκB. A full array of 
extracellular signals can activate the enzyme IκB kinase (IKK) comprising IKK alpha 
and/or IKK beta catalytic subunits and two molecules of NEMO. IKK, in turn, 
phosphorylates the IκB protein, which results in dissociation of IκB from NF-κB, and 
eventual degradation of IκB by the proteasome. NF-κB is now activated and 
translocated into the nucleus where it binds to specific sequences of DNA called 
response elements. The DNA/NF-κB complex recruits other coactivators and RNA 
polymerase. The latter transcribes DNA into mRNA which is then subsequently 
translated in proteins that have an effect on cell function (Gilmore, 2006).   
1.4 NUCLEAR RECEPTORS OF INTEREST, ESTROGEN RECEPTORS: HOW DO 
THEY SIGNAL AND WHAT ARE THEIR TARGETS?  
First and foremost, estrogens were considered to be essential in the development and 
maintenance of normal reproductive functions (Heldring et al., 2007).  However, 
estrogens are steroid hormones that have proved to regulate growth, differentiation, 
and function in a broad range of target tissues in the human body (Björnström and 
Sjöberg, 2005). Moreover, they also play very major roles in the immune system as 
34  
  
 
well as in the CNS in human body (Warner and Gustaffson, 2014). So much so that 
estrogens have been shown to improve the symptoms of Multiple Sclerosis and lower 
the risk of developing Alzheimer’s disease (AD) and Parkinson’s disease (PD). 
However, the mechanisms by which they exert these neuroprotective effects remain 
poorly understood (Baker et al., 2004). In this chapter we will describe the structure of 
estrogen receptors and how they interact with a ligand in order to account for 
phytoestrogens, and more specifically isoflavones, acting on estrogen receptors. 
Besides an overview of the role of estrogen receptors in the attenuation of 
neuroinflammation and neurodegeneration will also be discussed.    
1.4.1 Structure of estrogen receptors and their affinity to their ligands  
The most potent and dominant estrogen produced in the human body is 17 β-estradiol 
(E2) (Figure 8) but lower levels of the estrogens estrone and estriol are also present 
(Björnström and Sjöberg, 2005). E2 consists of a steroid structure, being its phenolic 
ring and the hydroxyl group on 17C position the ones responsible for its selectivity and 
affinity to estrogen receptors (ERs) (Heldring et al., 2007). The critical function of the 
phenolic A-ring for an estrogen to act on neuroprotection was determined by Green et 
al. (1997) and Behl et al. (1997). All modifications to the hydroxyl group at the 3-carbon 
resulted in total loss of neuroprotection, confirming that the phenolic nature of the Aring 
is critical for neuroprotection. Petron et al. (2014) also confirmed that three rings of the 
steroid nucleus are to the same extent necessary for neuroprotective activity.  ERs are 
distributed in the cytoplasm in their free form. However, estrogen binding to the 
receptor triggers a series of events starting with migration of the receptor from the 
cytosol into the nucleus. Estrogen receptors also occur within the cell nucleus (Huang 
et al., 2010).   
 
 
 
 
Figure 8. Molecular structure of the endogenous estrogen 17β-estradiol (E2). The 
rings are commonly named as A for the phenolic ring, B and C for the hexanes and D 
for the pentane.  
  HO 
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In the late 1950s, Elwood Jensen discovered and started the characterization of an 
estrogen binding protein, today recognized as ERα. In 1993, nearly three decades 
later, the first ERα knockout mouse was created. Such modification did not have any 
type of survival effect on the mouse. Soon after the characterization of the ERα 
knockout mouse, ERβ was discovered, and this discovery raised the question of 
whether survival of the ERα knockout mouse was due to ERβ substituting for the 
functions of ERα. ERβ knockout mice were made, and this was followed by double 
ERαβ knockouts. These different mouse models revealed that life is possible without 
either or both ERs but that reproductive functions are severely impaired (Heldring et 
al., 2007). Upon such results and further investigation, it was concluded that cellular 
signalling of estrogens is mediated through two estrogen receptors, ERα and ERβ 
(Olajide et al., 2014).   
Of note is that estrogen receptor ERα and β have different tissue/cell distributions and 
differential affinities for ligands and non-overlapping genes that they regulate. As a 
result, targeting these receptors differentially can lead to selective gene activation 
profiles (Huang et al., 2010). In the CNS, both receptors are widely expressed, in 
particular, in non-neuronal cells. Even though ERs are well known to have 
antiinflammatory effects, they may also have non-desired effects and it must be bared 
in mind in drug development. Evidence suggests that ERα also has mitogenic action, 
and therefore has been reported to trigger cancer; however, ERβ acts as tumour 
suppressor by opposing the mitogenic action of ERα (Fokialakis et al., 2012). The ERα 
mitogenic actions are due to estrogen acting as a morphogen that is a substance that 
determinates the pattern of tissue development in the process of morphogenesis, and 
the positions of the various specialized cell types within a tissue (Liu et al., 2002).   
Estrogen receptors belong to the nuclear receptor (NR) family of transcription factors. 
NR are a type of proteins within the cells responsible for sensing steroid and thyroid 
hormones among others. Such receptors are characterized by directly binding to the 
DNA, hence being also known as transcription factors resulting in the activation of the 
transcription process.     
A typical nuclear receptor usually contains four functional regions or domains (Figure 
9):   
- the A/B region is the N-terminal domain. A/B domain is not constant and it 
differs among the different subtypes and isoforms of NR.   
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- the C region with the DNA-binding domain (DBD) is a highly conserved region 
formed by two Zn fingers that binds to specific sequences of DNA called 
hormone response element (HRE), or in the case of estrogen receptors, 
estrogen response element (ERE), which are responsible for the dimerization 
of the NR;  
- the D region (hinge region) connects the C and E domains;  
- the E/F region so-called the ligand-binding domain (LBD) because it contains 
a hydrophobic ligand binding cavity it is located in the N-terminal part. It is also 
one of the regions more conserved in these type of receptors and alongside 
with DBD, LBD contributes to the dimerization of the receptor. Besides the 
ligand cavity it also contains binding sites for either coactivators or corepressors 
proteins whose shift will depend on the ligand (Heldring et al., 2007).   
 
Figure 9. Schematic representation of the structural and functional organization 
of nuclear receptors. a) Simplified representation of a common domain structure of 
NR; b) 3D illustration of the DBD region bound to the DNA upon ligand binding to LBD; 
c) enlarged view of LBD showing its characteristic three-layer sandwich structure; d) 
metabolic regulation of NR. Ligand-activated NR complex recruit coactivator proteins 
that increase transcriptional activity of the gene. NRs bind DNA as monomers, 
homodimers or heterodimers (Yang et al., 2014).   
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The substantial sequence homology between ERs endows them with comparable 
affinities for estrogen and ER agonists. It is worth mentioning that the sizes of the 
ligand pocket are incredibly broad as well as highly inducible both in size and in 
receptivity to molecules that are unrelated to endogenous ligand and for this particular 
reason, LBD has been the focus of structural study (Huang et al., 2010; Yang et al., 
2014). Due to the existence of a wide range of coactivators and corepressors in 
different cells, a ligand for ERs can act as an agonist in one type of cell but as 
antagonist in another. Therefore, partial agonists are typically the most promising 
candidates with limited undesired side effects (Huang et al., 2010).   
1.4.2 Mechanism of action of ERs in neuroprotection  
Both ERα and ERβ are present throughout the brain in humans and rodents, although 
their distribution throughout differs in most cases (Brann et al., 2007). These receptors 
mediate the effects of estrogens not only in the brain but also in the rest of the tissues 
and cells. This mechanism is based on their role as transcription factors in the cell 
nucleus and in their role in mediating rapid effects by cross-talk with other membrane 
localized receptors and cytoplasmic signalling pathways (Nilson and Gustaffson, 
2011).    
The three types of immune cells in the brain: astroglia, microglia and oligodendroglia, 
express a substantial number of classical nuclear and non-classical membrane ERs 
although in different quantities. With respect to microglia, it seems clear that E2 
attenuates microglial activation, phagocytic activity and nitric oxide production and that 
genetic elimination of ERα but not ERβ has the consequence of spontaneous reactive 
microglia in the brain (Kipp et al., 2016).   
Despite the controversy with the ERα subtype due to its association with the 
development of certain cancers such as breast cancer and prostate cancer, current 
reports strongly hint at that both ERα and ERβ are implicated in accomplishing 
substantial neuroprotection on neurological disorders through activation of various cell 
survival signalling pathways (see review: Chakrabarti et al., 2014). For example, in 
one study performed with ArKO (aromatase-deficient) mice – an important enzyme in 
the production of E2 – using ERα- or ERβ-selective agonist differentially protected 
against dopaminergic neuronal cell death in acoustic trauma (Brann et al., 2007).   
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ERs subtypes in Multiple Sclerosis  
The protective and possibly disease-modifying role of estrogen and the two ER 
subtypes has been investigated in experimental MS disease model. In this model, ERα 
revokes the disease at onset by inhibiting inflammatory responses, therefore, it 
appears to be the most important ER subtype in protecting against the development 
of MS. On the contrary, ERβ lacks the ability of abrogating this disease at onset. 
However, it was reported to promote recovery during the chronic phase of the disease 
by reducing demyelination and preserving axon numbers in white matter, as well as 
by decreasing neuronal abnormalities in grey matter resulting in the recovery of motor 
performance, which was initially severely impaired (Nilson and Gustaffson, 2011). 
Moreover, ERβ selective agonists reduced microglia stimulation in mice MS disease 
model (Wu et al., 2013).  
ERs subtypes Alzheimer’s Disease  
AD is the leading cause of dementia with two leading hallmarks: the accumulation of 
extracellular β amyloid (Aβ) peptide and the hyperphosphorylated protein tau in the 
form of neurofibrillary tangles.  However, in the recent years, emerging evidence 
support the implication of the innate immunity, and, in particular, the microglia in the 
pathogenesis of the AD. The aggregates of proteins deposited in the AD are 
recognized by microglia receptors and, consequently, they trigger an immune innate 
response, characterized by the release of several inflammatory mediators that 
contribute in the progression of the disease (Heneka, 2015). The important role of 
neuroinflammation is supported by findings that genes for immune receptors, including 
TREM (Guerreiro et al., 2013) and CD33 (Bradshaw et al., 2013) are associated with 
AD.   
Regarding the estrogens role in AD, it has been described an inverse correlation 
between estrogen levels and the incidence of AD by directly regulating Aβ levels by 
decreasing the production of Aβ and increasing its degradation. Estrogen’s 
neuroprotective effects may also be due to its regulation of tau phosphorylation. The 
decrease in tau phosphorylation is likely due to estrogen’s effect on tau kinases 
(Petron et al., 2014).  
Apparently, ERα has also a critical role in reducing Aβ accumulation in determined 
parts of the brain. Alike E2, the ERα-selective agonist PPT showed efficacy in reducing  
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Aβ accumulation in the hippocampus, subiculum, and amygdala but less effective than 
E2 in the frontal cortex, resulting also in enhancement in behavioral conduct. ERβ-
selective agonist DPN did not show such ability, but it did significantly reduce Aβ 
accumulation in the hippocampus and subiculum and it was partially effective in the 
frontal cortex and nearly as effective as E2 in the amygdala (Carroll et al., 2008).  
ERs subtypes Parkinson’s Disease  
PD is distinguished by progressive loss of dopaminergic neurons in the substantia 
nigra and by intracellular inclusions of aggregated α-synuclein (Lewy bodies). Alike 
AD, PD is also associated with activation of the brain inflammatory response, inducing 
a slow but irreversible phenomenon by which destruction and loss of dopaminergic 
neurons is carried out.   
Animal models of PD have been used to study the role of estrogens, selective estrogen 
modulators (SERMs), and ER subtype–selective agonists in the development of PD. 
A study in primates showed that 30 days of estrogen deprivation resulted in the 
permanent loss of more than 30% of the total number of substantia nigra dopamine 
cells. However, brief estrogen replacement therapy improved neuronal density. In 
mice, after administration of 1methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a 
compound that destroys dopaminergic neurons causing permanent symptoms of PD, 
treatment with E2 accomplished to prevent PD symptomatology. However, knockout 
mice for either ERα or ERβ were not fully protected against MPTP by E2 treatment, 
suggesting roles for ERα and ERβ in concert for dopamine neuroprotection (see 
review: Nilson and Gustaffson, 2011).    
1.5 PHYTOESTROGENS   
There is a rapidly growing body of evidence, that consumption of some plants 
containing phytoestrogens could be an additive  efficient tool to treat and prevent 
several dysfunctions and diseases related to aging mental processes, malignant 
transformation, metabolism, atherosclerosis, osteoporosis, cardiovascular diseases 
an reproduction, menopausal symptoms, and neurodegeneration (Sirotkin and 
Harrath, 2014). More than a decade has passed since the discovery that estrogens 
are potent neuroprotective substances and protect against cognitive decline during 
normal aging. These findings along with strong epidemiologic indication that described 
a delay in the age of commencement of Alzheimer’s disease in current and former 
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estrogen users led rapidly to the assessment of diverse phytoestrogens in the 
treatment of neurodegenerative diseases (Simpkins and Singh, 2008).   
Phytoestrogens (“phyto” = plant, “estrus” = sexual desire and “gene” = to generate) are 
non-steroidal plant derived natural products, related in structure to the estrogens 
generated within the endocrine system of mammalians. The most relevant 
mammalians’ estrogens are 17 β-estradiol (E2), estriol and estrone being the former 
stronger than its counterparts (Ososki and Kennelly, 2003). These estrogens possess 
18 carbon elements that shape an esteroid structure with a phenolic ring (A), which 
determines their selectivity and affinity for ERs, and a determinant functional group at 
17 position (Figure 8 and Figure 10). Due to such similarities at a molecular level, 
phytoestrogens also share functional resemblance with estrogens as either agonists 
or antagonists. As estrogen agonists, phytoestrogens mimic endogenous estrogens 
causing estrogenic effects. As estrogen antagonists, they may block or modify 
estrogen receptors and avoid estrogenic activity, causing antiestrogenic effects 
(Ososki and Kennelly, 2003). Such compounds are described as endocrine disruptors, 
which may be related to the initiation of breast cancer and deficiency of reproductive 
function. On the contrary, many other studies suggest that phytoestrogen, such as 
genistein, can reduce the risk of some hormone-related cancers. Therefore, 
considering the numerous effects that estrogen exert on the human body, these 
naturally occurring compounds serve as a good source of leading molecules for further 
modifications during the drug development process (Fokialakis et al., 2012; Wuttke et 
al., 2008) that could spark improvement in the treatment or prevention of 
neurodegenerative diseases.  
 
 
 
 
Figure 10. Structure of mammalian endogenous estrogen. a) Estriol and b) 
estrone. Five rings comprise their structure: (A) a phenolic ring that endows them with 
specificity and affinity for ERs, (B) and (C) are two cycled hexanes and (D) is pentane 
cycle with a substitute on position 17 also indispensable for their activity.   
a) b) 
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Popularly, phytoestrogens are also studied as SERMs due to a peculiar feature: a 
given compound can act as both agonist and antagonist depending on the tissue, ER 
and the amount of endogenous estrogen circulating (Ososki and Kennelly, 2003). 
Furthermore, phytoestrogens show a lower binding affinity than E2 and some show a 
higher binding affinity for ERβ than for ERα, which may indicate different pathways for 
their actions and explain tissue specificity (Kuiper et al., 1998).   
1.5.1 Classification of phytoestrogens   
On the basis of their chemical structure, which resembles E2, and in respect to 
biosynthesis patterns, phytoestrogens have been categorized in several groups:  
- flavonoids (chalcones, flavones, flavonols, flavanones, isoflavonoids, 
cathequines, pterocarpanes, rotenoids, anthocyanines, prenylflavonoids),  
- lignans,  
- anthraquinones and   
- saponins.   
Particular attention should be given to isoflavonoids, the subgroup of flavonoids that 
includes amongst others the chemical groups of isoflavones, isoflavanones, 
pterocarpanes, and coumestans (Sirotkin and Harrath, 2014).   
1.5.2 Similarities between isoflavones and estrogens   
Unlike some NRs such as the thyroid hormone receptor (TR) or the retinoic acid 
receptor (RAR) where the shape of the ligand binding cavity is well adapted to fit the 
cognate hormone, the ligand cavity for ERs appears spacious for E2. This allows ER 
to bind a wide range of compounds with strikingly diverse structures. In addition to 
estrogens, ERs also show affinity for environmental contaminants as well as 
phytoestrogens (Heldring et al., 2007).   
Epidemiological studies suggest that the consumption of plants with high 
phytoestrogens content are the reason why incidence of neurological disorders are 
lower among the Asiatic population than that in the Western world (Spencer et al., 
2012). In vitro and in vivo investigations have demonstrated that phytochemicals from 
plant sources, in particular flavonoids, exhibit anti-inflammatory activity.   
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Many phytoestrogens have been characterized and some of them have shown to have 
estrogenic activity. Isoflavones (Figure 11.a) are a major group of phytoestrogens that 
have been the focus of many studies and are known to display anti-inflammatory 
effects (Lin et al., 2007). By blocking the production of pro-inflammatory cytokines and 
chemokines such as TNF-α, IL-6 and IL-1β, as well as the activation of 
proinflammatory enzymes (phospholipase A2 –PLA2, COX-2, LOX, iNOS) isoflavones 
serve their anti-inflammatory functions (Yu et al., 2016).  Moreover, epidemiological 
studies on isoflavones have also demonstrated that a high intake of soy lowers the 
incidence of cardiovascular diseases, hormone-dependent cancers, menopausal 
symptoms and osteoporosis (Larkin et al., 2008). As such, isoflavones are 
characterized by eliciting either weak estrogen agonistic or antagonistic effects 
depending on the levels of endogenous estrogens and ERs (Yu et al., 2016). Despite 
their structural similarity to 17 β-estradiol, isoflavones have much higher bias for ERβ 
than for ER-α (Larkin et al., 2008).   
Among many others, the following isoflavones have been studied in depth: the 
aglycones, daidzein (4′,7-dihydroxyisoflavone) and genistein 
(4′,5,7trihydroxyisoflavone); the glycosides, daidzin and genistin; and biochanin A and 
formononetin, 4′-methyl ethers of daidzein and genistein (Figure 11.b). In plants, they 
can often be found as glycosides (Ibarreta et al., 2001). In processing, isolation and 
analysis, these compounds are readily degraded chemically or enzymatically to the 
aglycone (Ososki and Kennelly, 2003).  
As an example of the concordance between the isoflavones structure and human 
estrogens, in Figure 12 genistein is compared to estradiol. This isoflavone binds across 
the ligand-binding cavity very similarly to the natural ligand E2. For these types of 
molecules, the equivalent ring-A and the 3-hydroxyl groups occupy the same positions 
as the functional groups of E2. On the contrary, the antagonists often contain extended 
groups emerging from the center of their molecules, which directly impact on the E/F 
nuclear receptor region, blocking the site of coactivators and thus, affecting 
transcriptional activation (Figure 9) (Huang et al., 2010).    
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R1 = OH  R2 = OH  R3 = OH  Genistein  
R1 = O-Glu   R2 = OH  R3 = OH  Genistin  
R1 = OH  R2 = OH  R3 = OCH3  Biochanin A  
R1 = OH  R2 = H  R3 = OH  Daidzein  
R1 = O-Glu   R2 = H  R3 = OH  Daidzin  
R1 = OH  R2 = H  R3 = OCH3  Formononetin  
Figure 11. Isoflavones structures. a) General structure for isoflavones. b) Examples 
of isoflavones analogues.  
 
 
 
 
 
Figure 12. Comparison between the structure of an isoflavone derivative 
(genistein) and estrogen (estradiol), which shows the similarities between the 
two molecules (adapted from Pugazhendhi et al., 2008).   
a) 
b) 
Estradiol 
Genistein 
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1.5.3 Biochanin A and Formononetin: two remarkable isoflavones  
Isoflavones are primarily found in the Fabaceae family, that is in legumes such as soy, 
peanut (Arachis hypogaea L.) and clover (Trifolium spp.). In particular, soy seeds and 
red clover contain high levels of formononetin and biochanin A (Ososki and Kennelly, 
2003; Chen et al., 2008).  
Isoflavones are usually found in nature in their glycosides form. In humans, they are 
mainly hydrolyzed by the gut microflora and throughout an enterohepatic metabolism 
resulting into their free form. Such process allows for a better absorption and enhances 
the affinity of these compounds to ERs. Regarding formononetin and biochanin A they 
also undertake an O-demethylation to become derivatives of genistein and daidzein, 
respectively (Li et al., 2014).  
In particular, biochanin A (BCA, 5,7-dihydroxy-4’methoxyisoflavone) (Figure 11.b), is 
an ERβ-selective isoflavone in red clover and many other legumes. BCA is 
metabolized to the soy-derived isoflavone genistein, BCA conjugates, and genistein 
conjugates which can be detected in plasma and bile, happening to have a high 
clearance and a large apparent volume of distribution resulting in a poor bioavailability 
for both of them (<4%) (Moon et al., 2006).   
Formononetin  (FMN,  Formononetol  7-hydroxy-4’-methoxyisoflavona  4’-O-
methyldaidzein)  (Figure 11.b) is another phytoestrogen extracted from plant-derived 
red clover among others, which also possesses potent pharmacological activities, such 
as improving blood microcirculation, promoting cancer cell cycle arrest (Li et al., 2014), 
and regulating antioxidant effects. It is also one of the most important type of 
phytoestrogens found in legume plants such as Trifolium pratense and Glycine max, 
which exhibited anti-inflammatory effect on neurodegenerative diseases including 
Parkinson’s and Alzheimer’s disease by the inhibition of LPS-induced microglia 
activation and the generation of pro-inflammatory factors (Chen et al., 2008).  The 
metabolites of FMN are also essential in its estrogenic activity. FMN is metabolized to 
daidzein which is further processed into equol (Figure 13). However, equol is not 
metabolized equally in all humans due to differences in our intestinal bacterial 
composition which might account for their biological differences (Ososki and Kennelly, 
2003; Tolleson et al., 2002).   
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Figure 13. Equol structure. A metabolite from formononetin.  
All in all, it must be noticed that isoflavones are known to display low bioavailability 
due to poor solubility, extensive metabolism and rapid clearance (Fokialakis et al., 
2012). Thus, enhancing its bioavailability and/or metabolic stability with esters and 
especially carbamate esters is of our concern. Furthermore, potential selective ERβ 
isoflavones such as BCA and FMN can be a good strategy to avoid the carcinogenic 
effect of ERα. Nevertheless, it must not be forgotten that isoflavones metabolites also 
contribute to their biological effects which may differ from the original isoflavones 
digested (Ososki and Kennelly, 2003).    
1.6 SYNTHESIS STRATEGY: THE USE OF ESTERS AND CARBAMATES IN DRUG 
DESIGN  
Isoflavones contain a phenolic hydroxyl group, which is one of the most common 
functional group found in drug molecules such as estrogens and anticancer agents 
among others. Nevertheless, despite their functional characteristics, the presence of 
this group also endows the molecule with poor bioavailability and thus limited 
effectivity. Poor bioavailability is due to metabolic instability subjected to fast enzymatic 
biotransformation resulting in extensive first-pass metabolism. Moreover, the polarity 
of hydroxyl groups confers non-lipophilic character to the molecules, hindering the 
pass through the plasmatic membrane. These drawbacks of phenolic hydroxyl groups 
are pharmaceutically translated in the need of multiple doses of the drug to maintain a 
concentration-effective dose, and higher probability of accumulating toxic metabolites. 
In order to overcome such metabolism difficulties, a prodrug strategy would be to 
temporally mask polar groups resulting in an increased lipophilic molecule, which 
would promote membrane permeability (Férriz et al., 2010).   
Esterification of the hydroxyl group(s) has been one of the preferred prodrug strategies 
even for CNS delivery (Anderson, 1996). Many authors have described the 
46  
  
 
esterification with different mono- and poly-unsaturated fatty acids as one of the 
strategies followed to produce more active flavonoid derivatives. By adding an acyl 
group to the basic flavonoid skeleton, selectively acylated flavonoids are obtained with 
increase solubility and stability, resulting in potential biological activities. The nature 
and chain length of the acyl donor have a remarkable effect on the acylation reaction. 
Therefore, choosing an appropriate acyl donor significantly impacts the 
physicochemical and biological properties of the synthesized esters. The impact of 
acylation on biological activities has been copiously tested. In many modified 
flavonoids, their antioxidant, antiproliferative and citoprotective, anti-inflammatory, 
antibacterial and antifungal activities were improved by acylation. For example, the 
well-known flavonoid rutin improved its antioxidant activity upon acylation with 
unsaturated fatty acids, such as oleic and linoleic acid; isoquertin esters were shown 
to exhibit an antioxidant activity that depended on the acyl chain length; isoorientin 
esterification endowed it with higher lipophilicity; on the other hand, acylation of 
isoquercitrin resulted in a more effective compound at reducing inflammation via the 
NF-kB pathway (for review see Araújo et al., 2017).  
On the other hand, over the past few years, carbamate (Figure 14) derivatives have 
received much attention due to their application in drug design. Structurally, 
carbamates share similarities with esters and amides being therefore also functionally 
related.   
Carbamates are essential motifs in many approved medicines with clinical potential. 
For instance, rivastigmine (Figure 15.a) is used in the central nervous system to treat 
Parkinson’s and Alzheimer’s diseases. As another example, muraglitazar (Figure 15.b) 
is a PPAR α/Ƴ agonist which regulate glucose and lipid levels (Ghosh and Brindisi, 
2015). Moreover, several novel anti-cancer drugs and prodrugs derived from natural 
products have been obtained with the incorporation of such chemical group into the 
main molecule (Chaturvedi and Zaidi, 2015).   
N
H
R
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Figure 14. Structural representation of a carbamate group.  
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Figure 15. Chemical structure of a) rivastigmine and b) muraglitazar.  
A carbamate group usually endows the chemical compound to which it is attached with 
enhanced metabolic stability – primary against amino-peptidases, which are enzymes 
involved in the metabolism of peptide-like drugs - and improved permeability. This 
group also allows for two hydrogen bonding given the carboxyl (C=O) and amine (NH) 
groups instead of one as it would occur with an ester (-COO-) group alone. These 
features make of this chemical group a very good candidate to be present in drugs or 
prodrugs. On the other hand, Vecondio et al. have observed that the rate and level of 
their hydrolysis is key question for the duration and intensity of their pharmacological 
activity. Upon hydrolysis, carbamates esters release the parent phenol or alcohol drug 
and carbamic acid; the latest, is further discomposed to amine and CO2.  
All in all, carbamates and esters provide a good strategy to enhance isoflavones 
permeability though the CNS, improve their bioavailability and diminish their clearance 
rate. In the present project, we have compared natural compounds with and without 
this possible pharmacophore.   
1.7 GAP IN KNOWLEDGE  
Many studies have shown the health benefits of phytoestrogens, however, they also 
may exhibit side effects related to cancers depending on their affinity and specificity to 
ERs. ERα and ERβ are the main ERs found in human. Whilst ERα has been related 
to the development of carcinogenesis in breast and utereous tissues, ERβ has shown 
the ability to supress ERα, therefore, no side effects have been attributed to ERβ. BCA 
and FMN are two potent isoflavones with higher affinity towards  
a) 
b) 
48  
  
 
ERβ. Bearing this in mind, new inhibitors of neuroinflammation which activate ERs in 
the microglia without affecting ERs in the breast or ovaries could be protective without 
the expected side effects.   
1.8 OBJECTIVES OF THE STUDY  
Phytoestrogens have been shown to improve the symptoms and lower the risk of 
developing neurodegenerative diseases. In the light of hyperactivated microglia 
leading to an overproduction of inflammatory mediators, thus causing neurotoxicity 
and exacerbating the progress of such diseases, the present study aims to develop 
novel phytoestrogens that reduce neuroinflammation in the CNS.  
In order to accomplish this overall aim, the following specific objectives were 
established:  
- To synthesise bioactive derivatives phytoestrogens from the natural 
isoflavones Biochanin A (BCA) and Formononetin (FMN).  - To synthesize and study deoxybenzoins, which are intermediates in the 
synthesis of isoflavones, due to their structural similarity with isoflavones.  - To evaluate the synthesized compounds on the production of inflammatory 
mediators in LPS-activated microglia cells. 
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CHAPTER 2: MATERIALS AND METHODS  
Overview  
Upon the synthesis of the compounds, their separation and purification was performed 
by column chromatography unless otherwise stated. For the proper identification of 
the compounds obtained, nuclear magnetic resonance (NMR) and mass 
spectrophotometry techniques were employed. In order to test their anti-inflammatory 
properties, the determination of nitrite by Griess assay as well as ELISA immune 
assays for diverse cytokines were performed. Cell viability was assessed by XTT 
colorimetric assay. Lastly, primary inflammatory-involved proteins were detected by 
Western Blot.   
2.1 GENERAL CHEMISTRY METHODS  
All chemicals were of the highest available commercial purity. Starting materials and 
solvents, including the deuterated solvents used in the NMR study, were purchased 
from Aldrich Chemicals, stored according to the supplier’s instructions and used 
without further purification. All anhydrous reactions were carried out either under 
nitrogen or argon atmosphere. In some reactions, the solvents used were first dried by 
distillation prior to use. Thin layer chromatography was conducted on Merck glass 
silica gel 60 F254 and spots visualized using UV light and either vanillin-sulfuric acid 
reagent or permanganate (KMnO4) reagent. Liquid chromatography was performed on 
columns containing silica gel 60 Merck (63-200 µm). Solvent systems employed in 
chromatography are reported as volume to volume ratios. 1H (400.13 MHz) and 13C 
(100.62 MHz) spectra were recorded on a Bruker Ascend 400 spectrometer. Mass 
spectra experiments were performed on an Agilent 6210 TOF MS with a Dual ESI 
ionisation source (Annex I).  
2.1.1 Thin Layer Chromatography   
In order to monitor each reaction, thin layer chromatography (TLC) was conducted and 
spots visualized using UV light and either vanillin-sulfuric acid reagent or 
permanganate (KMnO4) reagent.  
TLC is a very simple technique but an exceptionally powerful analytical tool. Precoated 
silica chromatography plates are slightly acidic which confers the quality of being 
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suitable for running a wide range of compounds. This system is based both on the 
polarity of the compounds as well as on the polarity of the solvent. More polar 
compounds will be strongly retained than those with a lower polarity. Pre-coated silica 
gel plates need to be cut to size to fit the chromatography tank. They were marked 
with a pencil line to a height of around 1 cm, just above the depth of solvent poured 
into the tank. Samples were spotted with a suitable distance between them (0.5 cm). 
To do so, samples need to be dissolved in a suitable solvent prior to loading on the 
plates. The reaction mixture or unknown compound is spotted against starting material 
and a mixed spot of both. The plate was then placed vertically in the chromatography 
chamber. When the solvent front had travelled high enough the plate was removed 
and dried in air.   
In order to detect the spots, the dried plates were observed under UV light and if 
necessary, dipped in visualization reagents (Table 4) to identify UV invisible spots.    
Tabla 4. Recipes and comments on visualization reagents.  
 Stains  Recipe  Use/comments  
Vanillin  Vanillin (6g) in ethanol (250ml) + conc. H2SO4 (2.5 ml)  
Good general reagent.  
Gives a range of colours.  
Permanganate  
KMnO4 (3g) + K2CO3 (20g) 
+ 5% aq. NaOH  (5ml) + 
water (300 ml)  
Mainly  for  unsaturated 
compounds and alcohols.  
Gives yellow spots.  
  
Retention factor (Rf) is important to identify any compound formed in a given reaction 
since its value is constant under fixed conditions such as TLC plate, solvent system 
and temperature. Rf has positive values from 0 to 1 representing the position of the 
spot on the TLC plate. TLCs are also run to help to decide on the best mobile phase 
to achieve a good and easy purification afterwards grounded on the Rf value. If spots 
are running close together usually an Rf of about 0.3 is optimal, however, if they are 
well-separated a solvent system which retains the lower spot to a Rf 0.2-0.3 will usually 
work.   
Mathematically, Rf is represented as:  
Rf = a/b  
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 Where:  
- ‘a’ is the distance from the base line to the center of the spot on the TLC plate 
and  
- ‘b’ is the distance travelled by the solvent system measured from the base line.  
A well standardized solvent system is that consisting of an ethyl acetate (EtOAc) – 
petroleum ether mixture whose polarity can be easily adjusted by changing their 
proportions. The best TLC solvent system for each compound and reaction mixture 
had to be determined by trial and error.    
2.1.2 Column Chromatography   
Liquid chromatography is a standard method of purification based on the same 
principles than the TLC technique. When otherwise stated the purifications of the 
compounds synthesized were carried out by this methodology. The size in length and 
width of the column (Figure 16) was chosen according to the amount of sample 
obtained. The column was then packed with a mix of silica gel 60 Aldrich (63-200 µm) 
and the elution solvent system to give a slurry-like paste making sure to not generate 
any air bubbles through the process. The excess of solvent was released off the 
column and then a small amount of sand was poured to form a thin layer that would 
protect the silica gel. Subsequently, the reaction mixture dissolved in a suitable solvent 
(usually chloroform), was loaded carefully using a Pasteur pipette. Once the solution 
went through the sand to reach the silica, more eluent was immediately added to 
prevent the column from drying out. A reservoir was then attached to the column and 
gently filled up with a large volume of solvent system. The eluent was then slowly 
released and collected in marked test tubes. During the whole process, the solvent 
level was increased when necessary to ensure that the column did not dry out.   
TLCs were applied to each fraction collected to find the sections containing the desired 
compound. These sections were combined in a round bottom flask and the solvent 
removed by rotary evaporation, recovering thus a purified compound.  
In order to make sure that the sample was solvent-free, the dried material was once 
again dissolved in chloroform and taken to the rotatory vapor to be dried out. 
Thereafter, 30 mg were dissolved in a suitable deuterated solvent and transferred to a 
nuclear magnetic resonance (NMR) tube to run a complete NMR. Once the 
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characterization was completed, all compounds obtained were dissolved in dimethyl 
sulfoxide (DMSO), aliquoted and stored at -80°C.  
 
 
 
 
 
Figure 16. Representation of a column chromatography.   
2.1.3 Preparation of Biochanin A and Formononetin derivatives and intermediates  
Table 5 shows a summary of the compounds synthesized. The procedure used to 
prepare isoflavone analogs was carried out by adapting previously published methods 
(Fokialakis et al., 2004; Fokialakis et al., 2012).  
 
Table 5. Representation of the compounds synthesized and used in the present 
work. IUPAC: International Union of Pure and Applied Chemistry.  
Leading structure Derivatives and intermediates IUPAC denomination Name 
OOH
OH O
OCH3 
Biochanin A (BCA) 
OO
OH O
OCH3
N
H
O
 
5-hydroxy-3-(4-
methoxyphenyl)-4-
oxo-4H-chromen-7-yl 
undecylcarbamate 
Compound 1 
OO
OH O
OCH3
O
 
5-hydroxy-3-(4-
methoxyphenyl)-4-
oxo-4H-chromen-7-yl 
dodecanoate 
Compound 2 
O
OHHO
OH O
 
2-(4-methoxyphenyl)-
1-(2,4,6-
trihydroxyphenyl)etha
n-1-one 
Compound 3 
O
O
O
HO
 
Formononetin (FMN) 
O
O
O
OHN
O
 
3-(4-methoxyphenyl)-
4-oxo-4H-chromen-7-
yl undecylcarbamate 
Compound 4 
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Biochanin A derivatives   
Two BCA derivatives were synthesized in this work: 5-hydroxy-3-(4methoxyphenyl)-4-
oxo-4H-chromen-7-yl undecylcarbamate and 5-hydroxy-3-(4methoxyphenyl)-4-oxo-
4H-chromen-7-yl dodecanoate referred as compound 1 and compound 2 henceforth. 
For the latter, a previous step was necessary (Scheme 1) and subsequently the BCA 
derivatives, both compound 1 and 2, were made as shown in Scheme 2.    
  
Compound 1: 5-hydroxy-3-(4-methoxyphenyl)-4-oxo-4H-chromen-7-yl 
undecylcarbamate  
Synthesis of compound 1 was carried out as described by Nikolas Fokialakis et al. 
(2012). 100 mg of BCA (0.35 mmol) were dissolved in 20 ml of anhydrous ether and 
0.8 ml of anhydrous pyridine under stirring. The mixture was heated at 35°C on an 
oilbath and 0.05 ml of undecylisocyanate was added resulting in the formation of 
compound 1 (Scheme 2). The reaction was left overnight to assure that the maximum 
amount of reagents could interact. The crude material was concentrated by 
evaporating the remaining solvent with chloroform and dissolved one more time to run 
column chromatography in order to purify and separate the mixture obtained. Yield: 
65%.  
  
Compound 2: 5-hydroxy-3-(4-methoxyphenyl)-4-oxo-4H-chromen-7-yl 
dodecanoate  
For the preparation of compound 2, the carbonylic acid present in dodecanoic acid 
was first activated by making an acyl chloride (Scheme 1). In order to do that, 0.4 g of 
the acid was mixed in a round flask along with thionyl chloride (0.6 ml) and 
dichloromethane (10 ml) and the mixture was then refluxed for 3-4h. Once the time 
was completed, the solvents were removed, and the residue dissolved in DCM and 
the solvent removed again until total dryness. 100 mg of BCA (0.35 mmol) were 
dissolved in 20 ml of anhydrous ether and 0.8 ml of anhydrous pyridine under stirring. 
The mixture was heated at 35°C on an oil-bath and 0.05 ml of the acid chloride was 
added resulting in compound 2 (Scheme 2). The reaction was left overnight to assure 
that the maximum amount of reagents could interact. A salt precipitation was observed 
which was cleared out by filtration. The crude material was then evaporated and was 
dissolved in chloroform to be purified by column chromatography. Yield: 60%.  
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Scheme 1. Synthesis of the acid chloride. SOCl2 (thionyl chloride); DCM or CH2Cl2 
(dichloromethane).  
In both cases the reactions were monitored by TLC using a hexane-ethyl acetate (1:1) 
solvent system resulting in a good resolution.      
O
O
OOH
HO O
O
OOH
RO(C2H5)2O
35 ºC
(a), (b)
N
 
Scheme 2. Synthesis of BCA derivatives. (a) Reagents for compound 1: Py, CH3 
(CH2)10NCO; (b) for compound 2: Py, CH3 (CH2)10COCl.  
  
Biochanin A intermediate  
Compound 3: 2-(4-methoxyphenyl)-1-(2,4,6-trihydroxyphenyl)ethan-1-one  
Deoxybenzoins are intermediates in the synthesis of isoflavones which occur in 
several plant and marine sources. Due to structural similarities, in the present study, a 
BCA intermediate named 1-(2,4,6-trihydroxyphenyl)-2-(4-methoxyphenyl)ethanone, 
henceforth stated as compound 3 (Scheme 3), was synthesized and assessed 
subsequently.   
Because the synthesis of BCA consists of two consecutive reactions, the intermediate 
was synthesized following the method by Nikolas Fokialakis et al. (2012). The reaction 
is based on a Friedel-Craft reaction. Phloroglucionol (0.02 mol) and pmethoxy 
phenylacetic acid (0.02 mol) were dissolved into BF3·Et2O (5 mol equiv.) under 
nitrogen conditions. The mixture was stirred and heated at 80°C in an oil-bath for 90 
min creating an orange solution. Thereafter, an extraction was carried out by washing 
off the collected material thoroughly with saturated aq. NaHCO3 and ethyl acetate. 
When the reaction mixture was poured into the aqueous phase, an emulsion was 
observed and eliminated by adding brine (sodium chloride). Then, the organic phase 
was dried with magnesium sulphate, filtered and concentrated under vacuum. The 
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residue was purified twice by column chromatography on silica gel using firstly a 
mixture of dichloromethane and methanol (20: 1.2), and secondly, the same solvent 
system with a ratio of 22:1. The corresponding intermediate product, compound 3, was 
then isolated and purified. Yield: 45%. 
HO OH
OH
HO
O
O
O
O
OHHO
OH
2-(4-methoxyphenyl)-1-(2,4,6-trihydroxyphenyl)ethan-1-one
2-(4-methoxyphenyl)acetic acid
Phloroglucinol
BF3Et2O
80 ºC
 
Scheme 3. Synthesis of BCA intermediate (compound 3) through a Friedel-Craft 
reaction.  
  
Formononetin derivatives  
In order to synthesise a FMN derivative we first had to make FMN as detailed below. 
A mixture of resorcinol (3 mmol, 330 mg), 4-methoxyphenylacetic acid (3 mmol, 499 
mg) were dissolved into BF3∙Et2O (15.3 mmol, 1.9 mL) under argon. The mixture was 
stirred at 85 °C for 2 h. For cyclization the reaction mixture was cooled down to room 
temperature and dry DMF (20 mol equiv., 60 mmol, 4.65 ml) was added. The mixture 
was heated to 50 °C and a solution of methanesulphonyl chloride (9 mmol, 0.7 ml) in 
dry DMF (12 mmol, 0.9 ml) was added slowly. Thereafter, the reaction was brought up 
to 85 °C and stopped after 2 hrs (Scheme 4). The reaction mixture was cooled to room 
temperature and poured, without stirring, into a solution of ice-cold aq. sodium acetate 
(20%, 50 mL) due to the reaction of neutralization being exothermic. The solution was 
left under stirring for 10-15 min to assure a good extraction afterwards. The mixture 
was then extracted with ethyl acetate, and the organic layer was washed with water, 
dried (MgSO4) and concentrated. Yield: 43%. 
HO OH HO
O
O
B
F
F F
HO O
O
1. N2, 85
°
C, 2 h
2. rt, DMF
3. 50°C, MeSO2Cl/DMF
4. 85°C, 2 hr
+ +
2-(4-methoxyphenyl)acetic acid
7-hydroxy-3-(4-methoxyphenyl)-4H-chromen-4-one
O
O
 
Scheme 4. Synthesis of formononetin (FMN).  
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Compound 4: 3-(4-methoxyphenyl)-4-oxo-4H-chromen-7-yl undecylcarbamate  
In order to obtain the FMN derivative, to a solution of FMN (50 mg, 0.18 mmol) and 
triethylamine (0.4 ml, 0.56 mmol) in dried tetrahydrofuran (THF, 2 ml), undecyl 
isocyanate (0.04 ml) was added. The reaction mixture was stirred at 40-50ºC for 6 
hours (Scheme 5). After the reaction, the solvent was evaporated under reduced 
pressure and the resulting crude product was purified by crystallization. The compound 
was partially dissolved in methanol and boiled to fully dissolution and then cooled to 
room temperature to give a white powder which was then filtered under vacuum. The 
liquid phase was dried out under vacuum and an NMR was performed for each phase. 
Our desired compound, 3-(4-methoxyphenyl)-4-oxo-4H-chromen-7-yl 
undecylcarbamate (entitled compound 4 henceforth), was in the liquid phase, and the 
residual solid turned out to be excess of undecylisocyantate. Yield: 54%.  
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Scheme 5. Synthesis of FMN derivative (compound 4). THF: tetrahydrofuran.  
   
2.2 PHARMACOLOGICAL EXPERIMENTS  
2.2.1 Cell culture  
BV2 microglia, which are immortalised cells were used in this study. All the 
experiments were conducted on BV2 mouse microglia cells (ICLCATL03001) which 
was purchased from Interlab Cell Line Collection (Banca Biologica e Cell Factory, 
Italy).   
Cell cultures require an aseptic environment and a supply of nutrients to grow 
adequately. In terms of pH and temperature, the environment should be also stable. 
Therefore, upon thawing a vial of cells, these were sustained in humid atmosphere 
(95%), 5% of CO2 and 37°C. BV2 cells were cultured in Roswell Park Memorial 
Institute (RPMI) medium 1640 (Sigma Aldrich) supplemented with 10% fetal bovine 
serum (FBS) and 5 ml of sodium pyruvate (1mM). All culture supplements were also 
purchased from Sigma. LPS (Innaxon®) used is derived from Salmonella typhimurium, 
S-type (smooth/wild-type).  
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Subculturing semi-adherent cells  
BV2 microglia are by nature semi-adherent cells. For optimal growth and maintenance, 
these cells were cultured in 75 cm2 culture flasks. Once 80% of confluence was 
reached, cells were sub-cultured by washing them with Dulbecco's phosphatebuffered 
saline (DPBS) and using trypsin/ethylenediaminetetraacetic acid (EDTA) solution in 
order to detach the cells stuck on the flask wall and incubated for 1 minute at 37°C. 
RPMI was then added in order to inactivate the trypsin. The total volume was 
transferred to a 50 ml tube and centrifuged at 1,200 rpm for 5 minutes. The supernatant 
was removed and the pellet observed at the bottom flicked to its rupture. Cells were 
immediately re-suspended in fresh RPMI. Subsequently, cells were diluted 1/10 with 
RPMI and transferred to a new 75 cm2 flask.   
Seeding out cells into plates   
According to the type of experiment conducted, cells need to be seeded out into 
different wells with multiple volume capacities. However, in order to assure the validity 
of the experiments, the cell number needs to remain the same. Therefore, the cell 
quantification is very important. In our case, cell quantification was carried out 
manually by using a Neubauer's chamber. Once the cells reach the desired 
confluence, the medium needs to be changed to serum free medium for at least two 
hours before starting the stimulation.    
2.2.2 Determination of cell viability    
Viability of BV2 cells under-treatment was measured by 2,3-bis(2-methoxy-4-nitro-
5sulfophenyl)-5-[(phenylamino)carbonyl]-hydroxide (XTT) assay (Invitrogen). XTT is a 
colorless compound which upon reduction becomes brightly orange. Whether this 
reaction takes place means that cells are enzymatically active and therefore their 
viability has not been compromised. The absorbance is quantified 
spectrophotometrically and it is directly proportional to the alive number of cells. Such 
determination is relevant to determine whether or not the compounds tested are 
cytotoxic for the cells.  
In order to perform an XTT assay, BV2 cells were seeded out in a 96-well plate at a 
concentration of 15,000 cells per well. After 48 h incubation at 37°C, the medium was 
changed to serum-free medium. Thereafter, cells were treated with the compound 30 
min prior to stimulation with LPS for further 24h.  
58  
  
 
After 24 hours a 10 mM PMS (N-methyl dibenzopyrazine methyl sulfate) solution in 
PBS (phosphate-buffered saline) was prepared (3 mg PMS into 1 ml PBS). At the 
same time, 4 mg of XTT was dissolved in 4 ml of RPMI at 37°C. Subsequently, 10 µl 
of the PMS solution was added to the 4 ml of XTT and mixed. 25 µl of the latest solution 
was directly added to each well containing 100 µl of cell culture. After 2 h of incubation 
at 37°C, absorbance was read in a microplate reader (Infinite F50, Tecan) at 
wavelength of 450nm.   
2.2.3 Determination of nitrite production from BV2 microglia  
Nitric oxide (NO) is a molecular free radical produced by the nitric oxide synthases 
(NOSs) enzymes family which catalyze the production of NO from L-arginine. It is an 
important physiological messenger in the immune, nervous and cardiovascular 
systems. Due to its participation in these diverse systems, interest in measuring 
biological NO remains strong.   
High concentrations of NO may produce harmful effects in our organism. During an 
inflammatory process, the inducible isoform of nitric oxide synthase (iNOS) is 
responsible for the production of NO. This NO produces a neurotoxic activity reacting 
with other types of pro-inflammatory substances such as reactive oxygen species 
(ROS). However, an uncontrolled NO production may also boost ROS levels, 
generating oxidative stress and damaging adjacent neurons following 
neuroinflammation.   
The Griess assay is generally used for indirect measurement of NO. This assay relies 
on a diazotization reaction that was originally described by Griess in 1879. NO indeed 
has the feature of a short half-life, transforming almost instantly into its more stable 
version, nitrites (NO2-) and nitrates (NO3-). Nitrates are the product of a reaction 
between the NO and the oxihaemoglobin, being commonly originated in blood and 
plasma. On the contrary, nitrites are the sole stable product from the NO self-oxidation 
in aqueous solutions. Therefore, when performing a Griess assay, what it is actually 
being measured are the nitrites (NO2-) formed.  
The Griess Reagent system is based on the chemical reaction shown in Figure 17, 
which uses sulphanilamide (SA) and N-1-napthylethylenediamine dihydrochloride 
(NED) under acidic (phosphoric acid) conditions. NO2-  makes, under acidic conditions, 
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nitrous acid (HNO2) which gets protonated and fragmented releasing water and a 
nitrous cation (N=O+):  
HNO2 + H+        H2NO2+        H2O + NO+  
Subsequently, the nitrous cation interacts with an amine generating a nitrosamine 
product. Bearing this in mind, when the NO2- present in our sample enters into contact 
with SA, firstly, an aromatic diazonium salt is formed, which in turns reacts with the 
second reagent NED, delivering a pink colored compound giving thus, an indirect 
measure of the nitrite in the sample (Sun et al., 2003).  
  
Figure 17. Chemical reactions involved in the measurement of NO2- using the 
Griess Reagent System (Sun et al., 2003).  
For this purpose, BV2 cells were seeded at a density of 2 × 105 cells/ml and cultured 
until confluent. After that, pre-treatment with different compound concentrations 30 
minutes prior to stimulation with LPS (100 ng/ml) for a further 24 hours. After the 
incubation, culture supernatants were collected and centrifuged for 5 minutes at 2500 
rpm to remove cell debris. Levels of nitrite in culture media were measured using a 
Griess reagent kit (Promega, Southampton).  For a proper quantification, a nitrate 
standard curve was prepared in duplicate in a 96-well plate. Then, 50 µl of each sample 
was added to empty wells in the 96-well plate also in duplicate and other 50 µl of 
reagent 1 (SA) were added to all samples and incubated for 5-10 min protected from 
light. Afterwards, another 50 µl of reagent 2 (NED) were added to all wells and 
incubated in dark for further 5-10 min. Absorbance was read at 540 nm (Infinite F50, 
Tecan) and concentrations were calculated against a nitrite standard curve.    
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2.2.4 Determination of inflammatory cytokines by immunoassays  
Immune assays are widely used due to their sensitivity and specificity. They are based 
on the specific antigen-antibody reaction (Ag-Ab), which can be visualized through 
indirect mechanisms such as enzymes, fluorophores or isotopes. Such is the case of 
the enzyme immunoassay (EIA), which is characterized by using enzymes in order to 
detect the Ag-Ab reaction. Within this category, is found the Enzyme-Linked 
Immunosorbent Assay (ELISA). Generally, in this type of assay, the Ab is stuck on the 
surface of the well and the Ag is the molecule or substance we want to identify. This 
Ag also interacts with another Ab which is labelled with an enzyme. The substrate of 
the enzyme is colourless and it produces a coloured product upon enzyme activation, 
easily detectable by spectrophotometry.   
In this study, BV2 cells were seeded in 24-well plates as specified before, cultured until 
80% of confluence was reached and incubated with or without LPS (100ng/ml) in the 
absence or presence of the compounds desired (5, 10, 15 and 20 µM). Supernatants 
were collected after 24 h and centrifuged for 5 minutes at 2500 rpm. ELISA’s were 
performed that is plates were pre-coated with the coating antibody provided by the 
supplier in order to detect the Ag (in this case, cytokines) within the experimental 
sample. Hence, levels of TNFα, IL-6 and IL-1β in the supernatants were determined 
by specific ELISA kits against mouse cytokines (R&D Systems, China).   
One day prior to the experiment, a 96-well plate (Corning Costar® 9018) was 
precoated with unlabeled capture antibody diluted in coating buffer in a proportion of 
1:200. The coating buffer (5X) was firstly diluted with assay diluent to 1X. Thereafter, 
100 µl of this solution were transferred to each well of a high affinity, protein-binding 
ELISA plate. Plates were sealed to prevent evaporation and incubated at 4°C 
overnight. To detect concentrations of TNFα and IL-6 a standard curve was prepared 
by doing 6 two-fold serial dilutions (500, 250, 125, 62.5, 31.3, 15.6 and 7.8 pg/ml) 
starting from a stock solution of 500 pg/ml. Whilst to analyze the presence of IL-1β the 
initial stock solution was 2.000 pg/mL to give a standard curve of 1.000, 500, 250, 125, 
62.5 and 31.3 pg/mL. 1X assay diluent serves as the zero standard (0 pg/mL). All 
antibodies and reagents were diluted with 1X assay diluent. If needed, samples were 
also diluted with 1X assay diluent. The plate was thoroughly washed and blotted by 
tapping the plate upside down on absorbent paper. Subsequently, 200 µl of Assay 
diluent were added into all wells and incubated while shaking for 1h at 200 rpm. 
Afterwards, another washing was carried out and 100 µl of standard dilutions or 
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samples were added to appropriate wells and then incubated for 2 h on a rocker at 
200 rpm. The content of the plate was discarded and washed 4 more times. 100 µl of 
mouse detection antibody solution were added to each well and shook for a further 
hour. Another washing was carried out and 100 µl of Avidin were added for further 30 
minutes while shaking. In this step, a final washing was performed and 100 µl of 
Substrate Dilution were added. This substrate is tetramethilbenzidine, which is 
oxidated by a horseradish (HRP) enzyme giving a blue colour (Figure 18). The 
incubation time was carried out in the dark for either 15 min or until the desired colour 
intensity was achieved. The enzyme-substrate reaction was stopped by adding 100 µl 
of Stop solution (sulphuric acid 2N) to each well which veered the colour towards 
yellow. Absorbance was measured in a plate reader (Infinite F50, Tecan) at 
wavelength of 450nm. The concentration of cytokines present in the samples was 
calculated from the absorbance compared to the relevant standard curve.  
 
NH2H2N HN NH
HRP
H2O2 2 H2O+ +
(colourless) (blue)  
Figure18. Oxidation reaction of TMB by HRP.   
2.2.5 Determination of prostaglandin E2 (PGE2) by immunoassay  
Prostaglandin E2 (PGE2) is an arachidonic acid derivative released by activated 
microglia through the enzymatic action of cyclooxygenase-2 (COX-2). Several studies 
have shown that high levels of PGE2 regulate the production of inflammatory cytokines 
during neuroinflammation (Kim et al., 2015). This observation suggests that 
downregulation of PGE2 in activated microglia may be beneficial in the treatment of 
neuroinflammation and thus, in the neurodegenerative process.  
The determination of PGE2 levels in culture supernatant was conducted by enzyme 
immune assay (EIA) with a pre-coated ELISA kit from Arbor assay (USA) using the 
protocol provided by the supplier. Briefly, BV2 cells were seeded in 24-well plates as 
specified before, cultured until 80% of confluence was reached, pre-treated with 
different compounds and stimulated with LPS. Supernatants were collected after 24 h 
and centrifuged for 5 minutes at 2500 rpm. 100 µL of samples and standards were 
pipetted into wells in the plate. Thereafter, 25 µL of PGE2 conjugate (PGE2-peroxidase 
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conjugate in stabilising solution) and 25 µL of the PGE2 monoclonal antibody were 
added to each well.  The plate was covered with the plate sealer to be shaken at room 
temperature for 2 hours. The content of the plate was discarded and washed with 
freshly prepared washing buffer to remove non-specifically bound proteins or 
antibodies. 100 µL of 3,3’,5,5’-tetramethylbenzidine (TMB) substrate were added to 
each well and incubated 30 minutes without shaking. Finally, 50 µL of the stop solution 
(0.16M sulphuric acid) were pipetted to each well using a repeater pipette. The optical 
density generated was read in the plate reader at 450 nm. To the final concentration 
obtained, the inverse was applied in order to acquire the concentration of PGE2 
present in the samples.    
2.2.6 Cytosolic protein extraction  
In order to determine proteins of interest using Western Blot technique, it was 
necessary to separate target proteins from the tissue or cells. These are treated with 
a lysis buffer and subsequently are degraded mechanically to release the proteins. For 
that purpose and to get a sufficient amount of proteins, cells were cultured in a 6 well-
plate. In our case, a nuclear extraction kit supplied by Abcam was used.   
Briefly, after treating the cells, the stimulation was then stopped by placing the plate 
on ice. Throughout the entire process cells and their lysates were kept on ice to avoid 
protein degradation. Cells were washed with PBS (≈1 ml per well) followed by addition 
of 200 µl of a protease and phosphatase inhibitor cocktail comprised of 
radioimmunoprecipitation assay buffer (RIPA) lysis buffer in PMSF 
(phenylmethylsulfonyl fluoride) and incubated on ice for 15 min. The surface of each 
well was scraped and cells transferred to 1.5 ml tubes to be centrifuge for 10 min at 
13500 rpm at 4°C. In this case, the supernatant contains cytosolic proteins of 
interest; thus it is relocated to new labelled 1.5 ml tubes and stored at -80°C until 
further usage.   
2.2.7 Protein quantification  
Prior to conducting a Western Blot, protein must be quantified in order to ensure equal 
loading of proteins. In our case, Bradford’s method was conducted. Bradford reagent 
contains a hydrophobic colouring substance, Coomassie Blue, whose stability 
depends on the acid/base conditions of its environment. In an acidic environment, this 
reddish brown coloured reagent is protonated, however, when entering into contact 
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with disulphide bridges (S-S) of a protein it gets deprotonated, and its colour veers 
toward an intense blue. The intensity of this blue colour, measured by 
spectrophotometry, is proportional to the protein concentration in a sample.     
An aliquot of each sample is diluted, usually 1:10, and 5 µl thereof (in duplicate) is 
transferred into a 96 well-plate. 250 µl of Bradford reagent are added into each well 
and thereafter the absorbance is measured at 570 nm (Infinite F50, Tecan). In order 
to calculate the protein concentration of each sample, an albumin serum bovine (BSA) 
standard curve with known concentrations (2, 1, 0.5, 0.25, 0.125, 0.0625, 0.03125, 0 
mg/ml) is also conducted. Results are then interpolated on the standard curve 
according to a linear equation. Once the concentration is obtained, the volume of 
sample of each sample that needs to be loaded must be calculated. Depending on the 
protein being measured, the amount needed differs.    
2.2.8 Determination of protein expression by Western Blot  
The Western Blot technique or immunoblot of proteins, is an analytic technique 
employed for the detection of a specific protein from a complex mixture of proteins.  
Building on the physical characteristics of polypeptides, such as their size, electrical 
charge and shape, a complex mixture of proteins can be separated by electrophoresis 
in a gel matrix in the presence of electric current.  In the Western Blot, the electrical 
charge variable is controlled by adding a reducing agent which endows all proteins 
with the same negative charge; as a result, the disparity on the proteins distance 
travelled will be only affected by their shape and size. The term “blot” refers to the 
process of transferring biological macromolecules from a gel to a membrane and its 
posterior detection on its surface by specific antibodies. Details on these processes 
are explained below.   
Electrophoresis  
Electrophoresis allows the separation of proteins according solely to their physical 
features. For that purpose, usually polyacrylamide gels (PAGE) are used along with a 
reducing agent consisting of beta-mercaptoethanol (DTT) and sodium dodecyl sulfate 
(SDS). Therefore, all proteins will run towards the positive electrode and the smaller 
proteins will travel through the gel more easily than the bigger ones, resulting in 
separation in bands.  
 
64  
  
 
The four fundamental components of a polyacrylamide gel are:  
- Acrylamide;  
- Bisacrylamide;  
- TEMED (Tetramethylethylenediamine) and  
- APS (ammonium persulfate).  
The APS is the reaction initiator and in solution is found as a free radical, it is very 
active and acts upon acrylamide molecules to produce a linear polymer. Such reaction 
is catalyzed by TEMED and the bisacrylamide acts as a cross-linking reagent meaning 
that bisacrylamide is capable of creating cross-links between polyacrylamide chains, 
thus creating a network of polyacrylamide rather than unconnected linear chains of 
polyacrylamide.   
Depending on the size of the protein to be characterized, the percentage of acrylamide 
used on the confection of the gel differs (Table 6). The higher the percentage of 
acrylamide the smaller the size of the porous of the gel.   
Table 6. Percentage of acrylamide to be used on the confection of running gel 
depending on the size of the protein to be analyzed.  
Size of the protein  % Acrylamide  
200-130 kDa  8%  
130-40 kDa  10%  
40-15 kDa  15%  
In a Western Blot, the gel comprises 2 different parts: on top the “stacking gel”, which 
gathers the sample, and beneath the “running gel”.  The stacking gel is slightly more 
acidic (pH = 6.8) with a lower concentration of acrylamide, allowing all the proteins in 
the sample to be concentrated on the top of the running gel; in this way, all the particles 
are accomplished to be in the same initial conditions.  The running gel is more basic 
(pH = 8.8), and it is responsible for the separation of the proteins according to their 
molecular weight. Both gels are set up between two glasses whose distance between 
them will determine the thickness of the gel (from 0.4 mm to 2 mm).   
As mentioned above, the proteins are to be charged negatively so that all of them run 
to the same electrode. For this reason, a reducing buffer is used. This reducing buffer 
comprises:  
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- sodium dodecyl sulfate (SDS): charges the proteins negatively in a ration 1.4 g 
of SDS to 1 g of protein thus, the ration charge/mass of the proteins will be 
constant;  
- beta-mercaptoethanol or dithiothreitol (DTT): reduces disulphide bridges which 
breaks the structure of the proteins to their primary structure allowing the SDS 
to cover the proteins entirely;   
- glycerol: increases the density of the sample to be higher than that of the buffer; 
- Tris/HCl buffer (pH 6,8) and   
- Bromophenol blue: which possesses a higher electrophoretic mobility 
compared to the proteins, therefore it is positioned ahead being used as a 
marker of the front indicating when to stop the electrophoresis.  
Electrotransfer  
Once the proteins of the sample have been separated according to the molecular 
weight, they are transferred onto a membrane, which can be made out of nitrocellulose 
or polyvinylidene fluoride (PVDF). The latest have a higher protein retention capacity, 
physical resistance and a wide range of chemical compatibility, consequently these 
are the ones used in our case.  
There are different transferring systems but the most employed is the electrotransfer. 
This technique can be dry, semi-dry or wet. All of these are based on the same 
principles and only differ on the device used. The wet transfer requires a tank full of 
transfer buffer in which the gel obtained on the electrophoresis is soaked in contact 
with the PVDF membrane. Once the system is set up, the transference is produced 
when a constant electric current is supplied. It is an effective method but slower than 
that of the dry or semi-dry and it also requires more volume of transfer buffer.   
After the transference is completed, the membrane is then soaked into a blocking 
buffer, the most common of which are those formed by inert proteins such as BSA, 
skimmed milk, casein or gelatin. All of them are usually dissolved in PBS-tween 20. 
This step is necessary to avoid cross-talk reactions between the antibodies further 
employed and proteins that are of no interest in our analysis.   
Upon the blocking step, the membrane is incubated with a primary antibody specific to 
bind the protein to be detected. This antibody can be already labelled with or, on the 
contrary, require a secondary antibody labelled which will recognize the primary 
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antibody. In this case, the most common marking consists of the binding of an enzyme 
(such as the horseradish peroxidase [HRP] or the alkaline phosphatase [AP]) 
covalently to the antibody (Figure 19). This conjugated enzyme catalyzes the 
degradation of specific substrates generating a measurable signal that can be 
chromogenic, chemiluminescence or chemifluorescence (Figure 20). 
 
Figure 19. Diagram of the immunedetection of proteins on a Western Blot 
membrane. 
 
Figure 20. Diagram of the developing of membrane.  
PROTOCOL  
- Reduction and denaturation of proteins  
Upon quantification of the proteins in the samples by Bradford assay, the volumes 
corresponding to the same amount of protein in each sample were aliquoted in 
different 1.5 ml tubes. Each of them was completed with distilled water to an equal 
total volume, and then heated for 5 min at 99°C with a reducing buffer which contains 
DTT and SDS (5:1 v/v).  Samples were then ready to proceed with the Western Blot.  
 
67  
  
 
- Western Blot  
The electrophoresis device is set up with polyacrylamide gels inside and filled up with 
running buffer (refer to Annex I section 2 to see the composition). The same quantities 
of protein must be loaded in the wells of the gel, which generally has a 10% of 
acrylamide (see Annex II.1). The electrophoresis circuit is closed with a lid and then it 
is run for 50 min at 150V. Once this step was completed, the proteins on the gel were 
transferred to a PVDF membrane. These type of membranes have a large union 
capacity to proteins (100 – 300 µg/cm2) but are also completely hydrophobic and they 
would not get wet in aqueous solutions. For this reason and to make them compatible 
with a wet system, they need to be “activated”. To do so, the membranes are soaked 
in pure methanol and then dipped in water to wash them. Right after, they are ready 
to be soaked in transfer buffer (Annex II.2) in order to equilibrate the pH. In all cases, 
the type of transference employed was the wet transference (Bio-Rad) for 90 min with 
a current of 300 mA. The entire process is conducted at 4 °C (due to the process being 
exothermic) in continued agitation. In this system, the gel is always in contact with the 
membrane in a system assembled as shown in Figure 21. Since the protein have a 
negative charge, they migrate to the anode, in other words, from the gel to the 
membrane where they remain attached.   
Once the transference terminated, the membrane was incubated with skimmed milk to 
6% (p/v) diluted in PBS-Tween (PBS buffer supplemented with Tween 20 to 0.1% (v/v)) 
or BSA to 3% (p/v) diluted in PBS-Tween for 1h at room temperature and gentle 
agitation. The aim of this step is to block the areas of the membrane where proteins 
have not been transferred with inert proteins, thus reducing the unspecific union of the 
secondary antibody.    
 
Figure 21. Assembly of the transference process.  
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Upon the blocking the membrane is incubated with a primary antibody diluted (Table 
7) in skimmed milk (3%) or in BSA (1.5%) in PBS-Tween during 2h at room 
temperature. The membrane was then thoroughly washed with PBS-Tween with high 
speed agitation. Thereafter, the membrane was incubated with a secondary antibody 
(Alexa Fluor 680 goat anti-rabbit, Life technologies®) conjugated with HRP in a 
1:10000 dilution in skimmed milk (5%) in PBS-Tween for 1h at room temperature at 
slow speed agitation.  
Table 7. General information for primary antibodies used. 
Primary antibody Supplier Host Type Dilution 
Anti-iNOS Abcam Rabbit Monoclonal 1:1000 
Anti-COX-2 Abcam Rabbit Monoclonal 1:1000 
Upon the incubation time, a whole set of washes was repeated to remove the excess 
antibody. Finally, the bands with the protein of interest where visualized by a 
chemiluminiscent reaction, which employs horseradish peroxidase (HRP) to catalyze 
a reaction whose product is UV visible.  The HRP catalyzes the oxidation of luminol by 
using hydrogen peroxide (Immobilon™ Western HRP Substrate, Millipore). As the 
oxidated luminol turns into its baseline condition, it emits visible light, that was detected 
with a digital imaging capture system, LAS 3000 mini (Fujifilm) (Figure 22).   
 
Figure 22. Diagram of the protocol of a protein detection by Western Blot. Ab: 
antibody; HRP: horseradish peroxidase.   
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The densitometry analysis was conducted with Image Studio Lite v5.2. This program 
determines the optical density emitted and calculates the area under the curve. The 
integrated optical density (IOD) is obtained as a number. IOD values of the proteins 
are normalized against the respective loading control and represented in percentage 
in relation to the control (100%).  
2.2.9 Statistical analysis  
All experiments were performed at least three times and in triplicates unless otherwise 
stated. Data are expressed as mean ± SEM (standard error of the mean). For 
individual results, statistical analysis was performed using one-way analysis of 
variance (ANOVA) with post-hoc Student Newman-Keuls test (multiple comparisons).   
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CHAPTER 3: SYNTHESIS AND PHARMACOLOGICAL 
STUDIES ON BIOCHANIN A DERIVATIVES  
  
3.1 INTRODUCTION  
Neuroinflammation is a defense mechanism designed to protect the CNS against 
foreign pathogens and other type of injury. Therefore, acute neuroinflammation is a 
major and beneficial process that restores the homeostatic balance by eliminating the 
initial cause of the problem (Spencer et al., 2012). In the brain, not only glial cells are 
responsible for this restoration but also lymphocytes, monocytes and macrophages. 
However, microglia play a key role by repairing the injured tissue via the secretion of 
chemokines, cytokines and lipid mediators and clearing the debris.   
Despite its benefits, neuroinflammation and oxidative stress are also narrowly related 
to the pathogenesis of neurodegenerative diseases such as Parkinson’s and 
Alzheimer’s diseases. When the injury or any of the mechanisms that may activate 
glial cells are not resolved, cells remain permanently active and the brain enters a 
chronic neuroinflammation state. In this phase, microglia are termed as chronically 
active and fosters a chronic inflammatory state with the activation of precursors of pro-
inflammatory mediators that eventually results in the release of cytokines such as IL-
1β, IL-6, TNF-α, activation of the pro-inflammatory enzymes cyclooxygenase-2 (COX-
2) and the inducible nitric oxide synthase (iNOS), production of reactive oxygen 
species (ROS) and other series of events that may induce neurodegeneration and 
neurotoxicity (Ong et al., 2017). However, to date, the majority of drug treatments are 
addressed to treat the symptoms of the neurodegenerative disorders rather than 
preventing the underlying degeneration of neurons. Accordingly, there is a need and 
desire to develop novel therapies capable of preventing neuronal loss that trigger 
pathology in these diseases (Spencer et al., 2012).   
Even though isoflavones are the most absorbable and bioavailable flavonoids, 
phytoestrogens bioavailability, in general, has been a difficult issue to determine their 
physiological effects (Yu et al., 2016). Bioavailability of most phytochemicals in human 
tissues is very low because of a rapid clearance and even poorer in brain due to the 
BBB. Researchers have been developing strategies to solve this problem. Leading 
strategies involve the synthesis of highly lipid-soluble compounds and the 
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development of compounds undertaking uptake transport. Production of nanolipidic 
particles might be another approach (Ong et al., 2017).   
Since the first reported synthesis of an isoflavone analogue in 1925 by Baker and 
Robinson, a series of synthetic procedure have been developed in order to discover 
new and more potent isoflavones. Three methods have been extensively used: 
deoxybenzoin (Wähälä and Hase, 1991) and chalcone (Pavese et al., 2010) routes 
and the Suzuki cross-coupling reaction (Biegasiewicz et al., 2014). Among our 
objectives, testing the intermediates deoxybenzoin to assess their pharmacological 
properties was one of them. Therefore, in this project, the deoxybenzoin route leading 
to BCA was carried out.   
The deoxybenzoin route involves first the synthesis of the deoxybenzoin by a 
FriedelCrafts acylation, which consists of an electrophilic substitution of a phenol with 
a substituted phenylacetic acid. After the acylation, the deoxybenzoin undergoes 
cyclisation to give an isoflavone. On the other hand, BCA derivatives were synthesized 
based on that carbamates and esters have been used over the years due to their 
properties and application in drug design.   
BCA is an ER-β selective isoflavone mostly found in Trifolim pratense (family 
Fabeaceae) that has been shown to effectively suppress LPS-stimulated 
overproduction of cytokines and certain transcriptional factors by inhibiting the 
activation of the MAPK pathway in BV2 cells (Wang-Yang et al., 2014; Zhang et al., 
2015; Wang et al., 2016). Moreover, BCA was also shown to possess neuroprotective 
effects on PC12 cells by decreasing cell viability loss and apoptosis after Aβ25-35-
induced toxicity (Tan and Kim, 2016). However, a few drawbacks have been described 
when it comes to its potential in therapeutics. As any other isoflavone, poor water 
solubility, poor oral bioavailability (4.6%) due to stomach degradation, extensive 
hepatic first-pass metabolism and high susceptibility to hydrophilic degradation in 
gastrointestinal (GI) track, play a part in its characteristics (Sachdeva et al., 2016). In 
addition to the bioavailability issue, other studies have raised concern about the 
possible health risk of isoflavones. Isoflavones have also shown not only to promote 
proliferation of cancer cells but also to be cytotoxic for noncancerous cells (Hsu et al., 
2010). There are two hypotheses that attempt to explain such apparently contradictory 
health effects. One is the fact that isoflavones act on both ERs (α and β) and it is the 
balance between both of them that determine the biological outcome. The second 
hypothesis put forward is the role of epigenetics in cancer (Rietjens et al., 2013).   
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Few studies have modified the BCA pattern skeleton aiming at improving their 
pharmacological properties. In one study, the authors prepared a carboxy derivative 
of BCA (cBCA) by introducing a carboxymehyl group at position 6, based on a previous 
work in which carboxylation of the isoflavone genistein showed estrogenic and 
antiestrogenic properties similar to the SERM raloxifene (Somjen et al., 2005). 
Fokialakis et al. (2012) also prepared esters and carbamate esters BCA derivatives 
and evaluated their estrogenic and cancer chemopreventive activity, finding that one 
of them particularly displayed estradiol-like stimulation of gene expression as well as 
inhibition of proliferation of breast and endometrial cancer cells. Besides chemical 
approaches, developing drug delivery systems has been another attempt to enhance 
their bioavailability. Sachdeva et al. (2016) managed to produce enteric-coated 
microparticles that would directly arrive at the GI avoiding stomach degradation.   
Deoxybenzoins, on the other hand, are also non-steroidal molecules but hold the 
essential pharmacophores in order to interact with steroid receptors, therefore, acting 
like isoflavones in some cases. Such pharmacological properties are related to their 
chemical structure. Deoxybenzoins have the 4-OH and 4’-OH separated by an 
approximate distance of 12 Å and the presence of the aromatic rings A and B 
(Chandrasekharan et al., 2013). Some studies have also found that the intermediates 
deoxybenzoins may possess SERM-like properties. For instance, Papoutsi et al. 
(2007), synthesized a deoxybenzoin with a –Br at position 4’ that turned out to be 
antiestrogenic in breast cancer cells, and estrogenic on osteoblasts without causing 
stimulation of endometrial cells in vitro.    
On the basis of the above, in this project, BCA derivatives using chemical strategies 
were synthesized and the anti-neuroinflammatory effects of the pattern compound and 
its respective derivatives were studied in LPS-induced neuroinflammation in BV2 
microglia.    
3.2 RESULTS  
In order to fulfill the objectives proposed in the present study, different natural 
phytoestrogen derivatives were needed to be tested. As already mentioned in the 
section Material and Methods, we managed to synthesized two BCA derivatives and 
a BCA intermediate and conduct a preliminary study on their anti-inflammatory activity. 
This section refers to the structure and efficacy of BCA and its derivatives regarding 
the effectiveness on producing the desired effect.   
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3.2.1 Synthesis of BCA derivatives and its intermediate   
Compound 1: 5-hydroxy-3-(4-methoxyphenyl)-4-oxo-4H-chromen-7-yl undecylcarbamate  
After the reaction was completed, the presence of compound 1 in the crude extract 
was confirmed by TLC as described in section 2.1.1 The resulting spots after the 
reaction took place, were compared to BCA available commercially. A good resolution 
was achieved running TLCs with hexane/ethyl acetate (1:1) solvent system.   
TLC showed 3 spots under UV light and a fourth spot on the top was visualized with 
permanganate (KMnO4) reagent. By comparison with various TLCs, it was concluded 
that the higher spot, not being UV-active, was the remaining unreacted 
undecylisocyanate. The following UV-active spot was the desired compound, as was 
expected since the long side carbon chain provides it with less polarity than the starting 
material BCA, followed by the remaining BCA and a diffuse pyridine spot.  
Column chromatography was performed on the crude extract following the method 
described in section 2.1.2 using the same solvent system as in the TLCs as the eluent. 
In both cases, the compounds were effectively separated from the unreacted starting 
materials. The compound was recovered as a yellowish solid with a 65% yield.   
The 1H NMR, 13C NMR and mass spectra of the derivative synthesized fully agree with 
the expected structures.  
1 H-NMR (400 MHz, δ ppm, CDCl3): 12.8 (1H, s, OH), 7.98 (1H, s, H-2), 7.48 
(2H, d, J = 8 Hz, H-2’, H-6’), 7.01 (2H, d, J = 8 Hz, H-3’, H-5’), 6.86 (1H, d, J=1.5 Hz, 
H8), 6.62 (1H, d, J = 1.5 Hz, H-6), 5.10 (1H, t, J = 5.5 Hz, CH2NH), 3.82 (3H, s, OCH3), 
3.32 (2H, t, J = 7.5 Hz, CH2NH), 1.58–1.25 (18H, m, CH2), 0.91 (3H, t, J = 7.3 Hz, 
CH3).  
13C-NMR (100 MHz, δ ppm, CDCl3):  181.2 (C-4), 162.2 (C-7), 159.8 (C-5), 
156.9 (C-8a), 156.5 (C-4’), 153.2 (C-2), 153.0 (NHCOO), 130.1 (C-2’, C-6’), 123.9 
(C3), 122.6 (C-1’), 114.1 (C-3’, C-5’), 109.1 (C-4a), 104.9 (C-6), 100.4 (C-8), 55.3 
(OCH3), 41.3 (CH2NH), 31.9 (CH2CH2NH), 29.7-29.2 (5 CH2), 22.7 (CH3CH2), 26.7 
(CH3CH2CH2), 14.1 (CH3CH2).  
HRMS (Dual ESI): calculated m/z for C28H35NO6 482.2450, found 482.2537 
[M+H] +. Known compound (Fokialakis N et al., 2012).  
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Compound 2: 5-hydroxy-3-(4-methoxyphenyl)-4-oxo-4H-chromen-7-yl dodecanoate 
Upon the reaction to obtain compound 2, its proper characterization was conducted as 
for compound 1 above. The compound was recovered as a yellowish solid with 60% 
yield. The 1H NMR, 13C NMR and mass spectra of the derivatives synthesized fully 
agree with the expected structures.   
1H NMR (400 MHz, δ ppm, CDCl3): 12.75 (1H, s, OH), 7.87 (1H, s, H-2), 7.41 
(2H, d, J = 8 Hz, H-2’, H-6’), 6.9 (2H, d, J = 8 Hz, H-3’, H-5’), 6.67 (1H, d, J = 1.5 Hz, 
H-8), 6.5 (1H, d, J = 1.5 Hz, H-6), 3.78 (3H, s, OCH3), 2.5 (2H, t, J = 7.5 Hz, CH2), 
1.59–1.07 (20H, m, CH2), 0.87 (3H, t, J = 7.5 Hz, CH3).  
13C-NMR (100 MHz, δ ppm, CDCl3): 181.2 (C-4), 171.2 (COO), 162.37 (C-5), 
159.9 (C-7), 156.8 (C-8a), 153.2 (C-2), 130.0 (C-2’, C-6’), 124 – 122.5 (C-3, C-1’), 
114.1 (C-3’, C-5’), 109.4 (C-4a), 105.4 (C-6), 100.8 (C-8), 55.3 (OCH3), 34.4 – 22.6 
(CH2), 14.1 (CH3).  
HRMS (Dual ESI): calculated m/z for C28H34O6 467.2342, found 467.2428 
[M+H] +. Unknown compound.  
Compound 3: 2-(4-methoxyphenyl)-1-(2,4,6-trihydroxyphenyl)ethan-1-one  
The synthesis of BCA consists of two consecutive reactions. Firstly, an intermediate 
product is obtained by a Friedel-Craft reaction. Once this is separated and purified, a 
cyclization reaction takes place producing BCA. Given this two steps reaction, the 
intermediate (compound 3) was isolated. The reaction and work up of the crude 
material was performed as explained in section material and methods. The residue 
was purified twice by column chromatography on silica gel using firstly a mixture of 
dichloromethane and methanol (20: 1.2), and secondly, the same solvent system with 
a ratio of 22:1. The corresponding intermediate product 1-(2,4,6trihydroxyphenyl)-2-
(4-methoxyphenyl)ethanone was isolated as an brownish solid material with a yield of 
45%. The compound was identified by 1H-NMR.  
1 H NMR (400 MHz, δ ppm, DMSO): 12.21 (s, 1H), 10.36 (s, 1H), 8.91(1H), 7.12 
(d, J = 8.1 Hz, 2H), 6.83 (d, J = 7.5 Hz, 2H), 5.79 (s, 2H), 4.24 (s, 2H), 3.72 (s, 3H).  
Known compound (Fokialakis N et al., 2004).   
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3.2.2 BV2 cell viability  
In order to determine whether the anti-inflammatory effect of the synthesized 
compounds was not due to impaired viability of BV2 cells, an XTT viability assay was 
carried out after incubating the cells with the corresponding compounds for 24 h. 
Results (Figure 23) showed that there was no significant difference in the viability of 
cells treated with BCA, compound 1 and compound 2 at concentrations 5, 10, 15 and 
20 μM when compared with control (untreated) cells. However, the BCA intermediate, 
compound 3, produced statistically significant differences at the highest concentration.   
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Figure 23. Cell viability of BV2 cells for BCA compound and its derivatives and 
intermediate. Following treatment with various concentrations (5, 10, 15 and 20 µM) 
of the compounds and LPS (100 ng/ml) stimulation for 24h, cytotoxicity of BCA (a), 
compound 1 (b), compound 2 (c) and compound 3 (d) in BV2 cells was assessed by 
XTT assay. Values correspond to means of 3 independent experiments and are shown 
as the percentage of viable cells compared with the viability of negative controls 
(untreated cells). *p<0.05, **p<0.01, ***p<0.001 in comparison with LPS control. 
#p<0.05, ##p<0.01, ###p<0.001 in comparison with untreated cells.   
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3.2.3 Effects on nitrite production and iNOS protein expression  
Nitric oxide (NO) is an important mediator for the regulation of chronic 
neuroinflammation. Moreover, high concentrations of NO have been shown to be 
neurotoxic to adjacent neurons (Spencer et al., 2012). Therefore, the effects of the 
compounds a 5, 10, 15 and 20 µM were investigated for nitrite production in BV2 
microglia cells using Griess assay. Figure 24 shows that there was a marked increase 
in nitrite production (p<0.001) when cells were stimulated with LPS (100 ng/ml) alone, 
compared with unstimulated cells. However, pre-treatment with BCA and its 
derivatives effectively inhibited (p<0.001) NO release in a dose-dependent manner.  
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Figure 24. Effect of BCA, compound 1, compound 2 and compound 3 on nitric 
oxide (NO) in BV2 cells stimulated with LPS. This figure shows inhibition of NO 
release in LPS-activated BV2 cells by BCA (a), compounds 1 (b), 2 (c) and 3 (d). Data 
is expressed as mean ±SEM for 3 independent experiments. Statistical analysis was 
performed using one-way ANOVA with post-hoc Student Newman-Keuls test (multiple 
comparison). *p<0.05, **p<0.01, ***p<0.001 in comparison with LPS control. #p<0.05, 
##p<0.01, ###p<0.001 in comparison with untreated cells.  
NO PRODUCTION
0
50
100
150
   LPS (100 ng/ml)    -         +        +        +        +        +
Compound 1 (µM)    -         -         5       10       15      20
###
***
%
 o
f L
PS
 c
on
tr
ol
NO PRODUCTION
0
50
100
150
   LPS (100 ng/ml)    -         +        +        +        +        +
Compound 2 (µM)    -         -         5       10       15      20
###
##
#
***
**
%
 o
f L
P
S
 c
on
tr
ol
NO PRODUCTION
0
50
100
150
###
##
**
   LPS (100 ng/ml)    -         +        +        +        +        +
Compound 3 (µM)    -         -         5       10       15      20
%
 o
f L
PS
 c
on
tr
ol
a) b) 
d) c) 
77  
  
 
Nitric oxide is released by the inducible nitric oxide synthase (iNOS) and levels of both 
of them should be interrelated. Encouraged by the nitrite results, further studies were 
conducted with compound 1 in order to observe the correlation between NO and iNOS 
production. BV2 cells were pre-incubated with compound 1 for 30 minutes, followed 
by stimulation with LPS for further 24 hours. Upon the incubation time, cytoplasmic 
lysates were collected to analyse iNOS protein expression by western blotting. Overall, 
these results illustrate that compound 1 slightly reduces iNOS expression, in particular 
at a concentration of 15 µM (Figure 25).  
 
  
  
      
 
 
 
 
Figure 25. Effect of compound 1 on iNOS expression in BV2 microglia cells. 
Each bar represents a mean of the densitometry analysis by Western Blot of three 
independent experiments. Results are normalized with the housekeeping protein β-
actin and cells treated only with LPS are considered to undertake 100% of the 
expression of the enzyme. Significantly different to LPS: *p<0.05, **p<0.01, 
***p<0.001. Significantly different to untreated cells: #p<0.05, ##p<0.01, ###p<0.001.  
3.2.4 Effects on release of pro-inflammatory cytokines  
The primary cytokines which mediate chronic neuroinflammation are TNFα, IL-6 and 
IL-1β. The three of them were investigated in order to assess whether novel 
compounds were able to prevent the production of these important cytokines from 
LPS-activated BV2 microglia. Note that due to the fact that compound 3 was affecting 
the viability of the cells, there are no results for this compound.  
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The following graphs provide an overview of the drugs effect on cytokines. Single 
analysis for each of the chemical compounds revealed that BCA effectively decreased 
TNFα (p<0.001) and IL-1β (p<0.05) but increased IL-6 (p<0.01) (Figure 26).  
Compound 1 at various concentrations (5, 10, 15 and 20 µM) blocked TNFα (p<0.001), 
IL-6 (p<0.001) production gradually after stimulation with LPS for 24hr although no 
statistical differences were obtained for IL-1β (Figure 27). In contrast, compound 2 
activity was characterized by causing the opposite effects by increasing such cytokines 
as the concentration used was increased, in particular IL-6 production (p<0.001) 
(Figure 28).   
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Figure 26. Effect of BCA on TNFα, IL-6 and IL-1β production in LPS-activated 
BV2 microglia. Cells were stimulated with LPS in the presence or absence of BCA 
(5-20 μM) for 24 hours. Stimulation was terminated, and supernatants were collected 
and levels of (a) TNF-α, (b) IL-6 and (c) IL-1β were measured using ELISA. Data is 
expressed as mean ±SEM for 3 independent experiments. Statistical analysis was 
performed using one-way ANOVA with post-hoc Student Newman-Keuls test (multiple 
comparison). *p<0.05, **p<0.01, ***p<0.001 in comparison with LPS control. #p<0.05, 
##p<0.01, ###p<0.001 in comparison with untreated cells.   
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Figure 27. Effect of compound 1 on TNFα, IL-6 and IL-1β production in LPS-
activated BV2 microglia. Cells were stimulated with LPS in the presence or absence 
of compound 1 (5-20 μM) for 24 hours. Stimulation was terminated, and supernatants 
were collected and levels of (a) TNF-α, (b) IL-6 and (c) IL-1β were measured using 
ELISA. Data is expressed as mean ±SEM for 3 independent experiments. Statistical 
analysis was performed using one-way ANOVA with post-hoc Student Newman-Keuls 
test (multiple comparison). *p<0.05, **p<0.01, ***p<0.001 in comparison with LPS 
control. #p<0.05, ##p<0.01, ###p<0.001 in comparison with untreated cells.   
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Figure 28. Effect of compound 2 on TNFα and IL-6 production in LPS-activated 
BV2 microglia. Cells were stimulated with LPS in the presence or absence of 
compound 2 (5-20 μM) for 24 hours. Stimulation was terminated, and supernatants 
were collected and levels of (a) TNF-α and (b) IL-6 were measured using ELISA. Data 
is expressed as mean ±SEM for 3 independent experiments. Statistical analysis was 
performed using one-way ANOVA with post-hoc Student Newman-Keuls test (multiple 
comparison). *p<0.05, **p<0.01, ***p<0.001 in comparison with LPS control. #p<0.05, 
##p<0.01, ###p<0.001 in comparison with untreated cells.    
3.2.5 Effects on Prostaglandin E2 production and COX-2 protein expression  
Prostaglandin E2 (PGE2) is an arachidonic acid derivative released by activated 
microglia through the enzymatic action of cyclooxygenase-2 (COX-2). The effects of 
the compounds (5, 10, 15 and 20 μM) on PGE2 were evaluated after 24 h of stimulation 
on LPS-activated BV2 microglia. On the graphs below (Figure 29) PGE2 results are 
plotted for BCA and its derivatives. LPS-treated BV2 cells produced detectable levels 
of PGE2 compared to untreated microglial cells. BCA specially produced a significant 
(p<0.001) reduction of PGE2 production at all concentrations. However, for compound 
1 the inhibition was not significant and treatment with compound 2 resulted in an 
increase in PGE2 production (p<0.01).  
Due to the direct relationship between PGE2 and COX-2, the expression of the latter 
for compound 1 was also evaluated by western blotting. Overall, these results illustrate 
that compound 1 slightly reduces COX-2 expression, in particular at a concentration 
of 15 µM (p<0.01) (Figure 30).  
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Figure 29. Effect of BCA, compound 1 and compound 2 on PGE2 production in 
LPS-activated BV2 microglia. Upon treatment with compounds and BV2 cells 
stimulation with LPS (100 ng/ml), supernatants were collected and PGE2 measured by 
ELISA. BCA (a) significantly reduced PGE2 formation while compound 1 (b) its 
reduction is almost undetectable and compound 2 (c) produces an increase on PGE2. 
Data is expressed as mean ±SEM for 3 independent experiments. Statistical analysis 
was performed using one-way ANOVA with post-hoc Student Newman-Keuls test 
(multiple comparison). *p<0.05, **p<0.01, ***p<0.001 in comparison with LPS control. 
#p<0.05, ##p<0.01, ###p<0.001 in comparison with untreated cells.   
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Figure 30. Effect of compound 1 on COX-2 expression in BV2 microglia cells. 
Each bar represents a mean of the densitometry analysis by Western Blot of three 
independent experiments. Results are normalized with β-actin and cells treated only 
with LPS are considered to undertake 100% of the expression of both enzymes. 
Significantly different to LPS: *p<0.05, **p<0.01, ***p<0.001. Significantly different to 
untreated cells: #p<0.05, ##p<0.01, ###p<0.001.   
3.3 DISCUSSION  
Neuroinflammation is a critical component of a broad array of neurodegenerative 
diseases. Moreover, increasing evidence suggests that chronically hyperactivated 
microglia cells are mainly responsible for the exacerbation and maintenance of this 
condition. In this project, neuroinflammation inhibitory actions of the dietary isoflavonoid 
BCA, highly present in red clover; compound 1, a carbamate ester BCA derivative; 
compound 2, an ester BCA derivative and compound 3, the deoxybenzoin BCA 
intermediate were investigated in LPS-activated BV2 microglia.  
Microglia stimulation with bacterial lipopolysaccharide (LPS) derived from Salmonella 
typhimurium resulted in an increase in the production of pro-inflammatory cytokines like 
TNFα, IL-1β and IL-6 and other inflammatory modulators such as nitric oxide. Because 
disproportionate nitric oxide levels have proved to be detrimental to neurons in the 
brain, as it is capable of inducing protein misfolding during post-translational 
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modifications in the microglia, therefore, boosting transcription factors activation like 
NF-ĸB and further overstimulating the inflammatory process in the brain (Vauzour et 
al., 2015), NO levels were also evaluated. Nitric oxide is released by the inducible nitric 
oxide synthase and levels of both of them should be interrelated. Activated microglia 
are also known to produce prostaglandins whose production is controlled by COX-2 
enzyme (Morales et al., 2014). LPS stimulated BV2 cells also generated PGE2, which 
is a major eicosanoid found in many CNS related inflammatory diseases and is a 
primary target for non-steroidal anti-inflammatory drugs (Wang et al., 2015).  
The present study confirms BCA’s suppressive capability on BV2 cells inflammatory 
response. BCA effectively reduces the production of TNF-α and IL-1β in LPS-activated 
BV2 microglia, suggesting that the compound is capable of inhibiting 
neuroinflammation. However, it did not significantly suppress IL-6 release. Such results 
contrast other previous studies in which IL-6 had been evaluated after treatment with 
BCA in primary microglial cells. In this latest study, BCA effectively decreases IL-6 
along with the other CKs (Wang et al., 2016). Such differences may be due to the 
nature of the cells, since primary microglia cells slightly differ from the two commercially 
available cell lines BV2 and N9 (Stansley et al., 2012).  It is worth mentioning that IL-6 
not only has been associated with pro-inflammatory processes but can also play a 
protective role by various means like promoting microglia cells differentiation into their 
phagocytic phenotype, or by inhibiting others CKs production (e.g.: TNFα) (Erta et al., 
2012). After stimulation with LPS, BV2 cells were shown to increase the production of 
nitric oxide and PGE2. Upon treatment with BCA, both inflammatory modulators, NO 
and PGE2 decreased.   
Compound 1 was made from BCA by the addition of a carbon long chain through the 
formation of a carbamate ester. Preliminary results for NO and CKs illustrated a good 
response of BV2 towards the treatment with compound 1 by reducing all these 
inflammatory modulators. Encouraged by such results, PGE2, iNOS and COX-2 were 
furthered studied. Nevertheless, PGE2 experiments did not show statistical 
significances which correlates with the studies performed on COX-2 by western 
blotting. On the other hand, reduction on iNOS levels were not as pronounced as for 
the nitric oxide ones. Such differences might be due to the accuracy differences among 
both techniques. All in all, it must be noticed that significant differences (p<0.05) when 
using 15 µM of compound 1 were observed for both iNOS and COX-2.   
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As for compound 2, even though it showed effectiveness on NO reduction, it was not 
effective at blocking TNFα, IL-6 and PGE2 release. In fact, it significantly boosted the 
discharge of these pro-inflammatory modulators. Such differences must be due to the 
compound structures. To the natural pattern BCA, a saturated long chain was added 
to the –OH in position 7 by esterification. The lack of a free hydrogen in that position 
must have been the cause of such unfavourable results since it is widely known that 
the OH in the fourth carbon (4’-OH) and in the seventh (7-OH) are essential to mimic 
those of the estradiol in position 3 and 17 (Fokialakis et al., 2012).  
Compound 3 was synthesized to test the effect of deoxybenzoins, which are 
intermediates in the synthesis of isoflavones, due to their structural similarity with 
isoflavones. However, cytotoxic assays confirmed that the reduction of NO observed 
by compound 3 were due to the compound being cytotoxic for the cells. For this reason, 
this compound was excluded from the rest of the analysis conducted. In relative binding 
affinities for ERα and ERβ experiments, Fokialakis et al. (2004) suggested that 
compound 3 exhibited a moderate affinity towards ERα. Hu et al. (2013) also isolated 
11 deoxybenzoins from Arundina graminifolia to assess their cytotoxicity towards five 
cancer cell lines, indicating that certain deoxybenzoins can also serve to target 
malignant cells.   
Taken together, results on BCA experiments suggest that it may inhibit 
neuroinflammation in BV2 microglia; however, its deoxybenzoin intermediate 
(compound 3) did not have the same properties and instead showed to be cytotoxic for 
these cells. On the other hand, the addition of a long carbon chain in order to augment 
lipophilicity using the formation of an ester and a carbamate ester resulted in completely 
different outcomes. While compound 1, that of the carbamate ester, exhibited an anti-
inflammatory effect on BV2 cells, compound 2 increased the production of pro-
inflammatory modulators. Further investigation on molecular studies, ligand binding 
assays, half maximal inhibitory concentration (IC50) evaluation and transactivation 
assays would shed some light in determining the mechanism by which these 
compounds displayed such differences.  
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CHAPTER 4: SYNTHESIS AND PHARMACOLOGICAL 
STUDIES ON FORMONONETIN DERIVATIVES  
  
4.1 INTRODUCTION  
Due to the evidences of that inflammation plays an important role in 
neurodegenerative diseases, several non-steroidal anti-inflammatory drugs (NSAID) 
have been the focused of many epidemiological and clinical trials reducing the risk of 
developing neuroinflammation (Chattopadhyay et al., 2010; Vernieri et al., 2013). 
Nevertheless, following a therapy on NSAIDs has not been as promising with AD 
patients. This is not very surprising if one bears in mind that neurodegenerative 
diseases are very context-dependent and stage-dependent (see review: Heneka et 
al., 2015). In addition, these NSAIDs usually have adverse effects when used in long-
term treatments, having a detrimental impact at a gastrointestinal, cardiovascular and 
renal level as well as increased ability to acquire resistance to these drugs (Minghetti 
et al., 2004).   
Therefore, other types of strategies are gaining ground, that is promoting the use of 
medicinal plants as preventive strategies to delay the onset of the diseases. As 
reviewed in Chapter 1.6, many authors have taken advantage of the presence of 
hydroxyl groups in isoflavones to enhance the bioavailability characteristics of phenolic 
hydroxyl compounds by esterification and the addition of carbamate ester groups. In 
fact, one of the best and most reliable strategies for delivering active drugs with low 
BBB crossing ability is to design an effective prodrug that can potentially cross the 
BBB to release the parent drug after hydrolysis (Dholkawala et al., 2016). Following 
this strategy, a FMN carbamate ester derivative was synthesized in this project.  
FMN (Formononetol 7-hydroxy-4’-methoxyisoflavona 4’-Omethyldaidzein) is an 
isoflavone found in red clover plant and widespread in the Leguminosae family (Larkin 
et al., 2008) that has been reported to possess many potent pharmacological activities 
including antitumor, antihypertensive, antibacterial, antiviral, antioxidant and 
antiangiogenic effects (Mu et al., 2009; Li et al., 2014; Sun et al., 2011; Wu et al., 
2015). Its anti-inflammatory effects have also been widely proven, for instance, in 
pancreas cells (Wang et al., 2012) by inhibiting NF-kB, and also in lung injury in mice 
(Ma et al., 2013). Moreover, FMN also seems to induce neuroprotection by up-
regulating NRF2 in TBI (traumatic brain injuries) models (Li et al., 2014), and prompt 
dopaminergic neurons protection in a dose-dependent manner in rat mesencephalic 
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neuron-glia cultures (Chen et al., 2008). Unpublished research conducted in our group 
has proven FMN efficacy at reducing the release of pro-inflammatory modulators by 
BV2 microglia cells via ERs.  
Daidzein is the metabolite of FMN. The estrogenic effect of daidzein is largely achieved 
by its biotransformation to equol via a gut microflora-dependent metabolism (Tolleson 
et al., 2002). However, by the O-methoxy substitutions of the free phenolic hydroxyl 
group at 4’ results in FMN, whose lipophilicity is shown to be enhanced. Moreover, a 
study carried out by Srivastava et al. (2013) that identified an isomer of FMN (Isoformo) 
demonstrated that Isoformo reverses established osteopenia in adult rats likely via its 
pro-survival effect on osteoblasts.  
In addition, several studies have modified the FMN pattern skeleton aiming at 
improving their pharmacological properties. For example, Li et al., (2016) synthesized 
a 7-phosphoramidate derivative capable of inducing apoptosis in cancer cells and Ren 
et al., (2012) created a mononetin nitrogen mustard derivative that was able of 
promoting both cell cycle arrest and initiate apoptosis. Fu et al. (2017) have recently 
design and synthesized a battery of antitumor FMN derivatives by the formation of a 
formononetin-dithiocarbamate (Figure 31) hybrid with antitumor related properties with 
IC50 values of even 1.97 µM. By following a molecular hybridation strategy, they have 
endowed the new molecules with several drug essential properties: i) the 
dithiocarbamate group possess drug-like porperties, ii) the FMN serves as the 
pharmacophore fragment, and iii) an alkoxyl chain for lipopholicity.   
 
 
 
 
 
 
 
Figure 31. Formononetin-dithiocarbamate synthesized by Fu et al. (2017) 
following a rational molecular hybridation strategy.  
Dithiocarbamate   
Lipophilicity group 
Aliphatic amines 
Pharmacophore 
(Formononetin scaffold) 
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On the basis of the above, in this project, a carbamate ester FMN derivative was 
synthesized and the anti-neuroinflammatory effects of the pattern compound and the 
derivative were studied in LPS-induced neuroinflammation in BV2 microglia.   
4.2 RESULTS  
In order to fulfill the objectives proposed in the present study, different natural 
phytoestrogen derivatives were needed to be tested. As already mentioned in the 
section Material and Methods, we managed to synthesized FMN and one derivative 
and make a preliminary study on their anti-inflammatory activity. This section refers to 
the structure and efficacy of FMN and its derivative regarding the effectiveness on 
producing the desired effect.   
4.2.1 Synthesis of Formononetin and its derivative  
Formononetin: 7-Hydroxy-3-(4-methoxyphenyl)-4H-1-benzopyran-4-one, 7-Hydroxy3-(4-
methoxyphenyl)chromen-4-one or 7-Hydroxy-4′-methoxyisoflavone)  
In order to synthesize a FMN derivative we first had to make FMN as described in 
section materials and methods. After the reaction was completed and the crude 
material was extracted with ethyl acetate, the resulting product was again dissolved in 
ethyl acetate, brought to simmer and left to cold down. Two phases were observed, 
the one on the top was brownish and that on the bottom white. These were separated 
by decantation. This process was repeated as many times as needed to purify the 
white powder which was the compound of interest. This reaction gave a yield of 45%.   
The 1H NMR and 13C NMR of the FMN fully agree with the expected structures.   
1H-NMR (400 MHz, δ ppm, DMSO):  10.82 (1H, s, OH-7), 8.35 (1H, s, H-2), 
7.97 (1H, d, J = 8.8 Hz, H-5), 7.51 (2H, d, J = 8.8 Hz, H-2’, H-6’), 6.99 (2H, d, J = 8.8 
Hz, H-3’, H-5’), 6.94 (1H, dd, J = 2.2, 8.8 Hz, H-6), 6.87 (1H, d, J = 2.2 Hz, H-8), 3.79 
(3H, s, OCH3).  
13C-NMR (100 MHz, DMSO): 175.1 (C=O), 163.0 (qC), 159.4 (qC), 157.9 (qC), 
153.6 (CH), 130.5 (2 CH), 127.8 (CH), 124.7 (C), 123.6 (C), 117.1 (C), 115.6 (CH), 
114.1 (2 CH), 102.6 (CH), 55.6 (CH3).   
HRMS (Dual ESI): calculated m/z for C16H12O4 269.0736, found 269.0808 
[M+H]+. Known compound. 
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Compound 4: 3-(4-methoxyphenyl)-4-oxo-4H-chromen-7-yl undecylcarbamate  
The synthesis of compound 4 was undertaken as described in the section Materials 
and Methods. The corresponding compound was isolated as a yellow solid material 
with a yield of 55%.   
1H NMR (400 MHz, δ ppm, DMSO): 7.9 (1H, s, H-2), 7.6 (1H, d, J = 8 Hz, H5), 
7.5 (2H, d, J = 8 Hz, H-2’, H-6’), 7,4 (1H, t, J = 5.5 Hz, CH2NH), 6.9 (2H, d, J = 8 Hz, 
H-3’, H-5’), 6.3 (1H, d, J = 2.2 Hz, 8 Hz, H-6), 5.9 (1H, dd, J= 2.2 Hz, H-8), 3.8 (3H, s, 
OCH3), 3.6 (2H, t, J = 7.5 Hz, CH2NH), 1.7 (2H, m, CH2), 1.3-1.1 (16H, m, CH2), 0.8 
(3H, t, J = 7.5 Hz, CH3).  
13C-NMR (100 MHz, δ ppm, DMSO): 175.3 (C-4), 159.8 (C-4’), 157.8 (C-7), 
154.7 (C-8a), 153.2 – 153.4 (C-2, COO), 130.1 (C-2’, C6’), 127.2 (C-5), 124.8 (C-1’), 
123.5 (C-3), 122.4 (C-4a), 116.3 (C-6), 114.2 (C-3’), 111.1 (C-8), 55.8 (OCH3), 40.3 
(NHCH2), 26.4-31.9 (CH2), 22.7 (CH2), 14.1 (CH3).  
HRMS (Dual ESI): calculated m/z for C28H35N1O5 466.5654, found 466.5741 
[M+H]+. Unknown compound.  
4.2.2 BV2 cells viability   
In order to determine whether the anti-inflammatory effect of the synthesized 
compounds was not due to impaired viability of BV2 cells, an XTT viability assay was 
carried out after incubating the cells with the corresponding compounds for 24 h. 
Results (Figure 32) showed that there was no significant difference in the viability of 
cells treated with either FMN nor compound 4 at concentrations 5, 10, 15 and 20 μM 
when compared with control (untreated) cells.   
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Figure 32. Cell viability of BV2 cells for FMN and compound 4. Following treatment 
with various concentrations (5, 10, 15 and 20 µM) of the compounds and LPS (100 
ng/ml) stimulation for 24h, cytotoxicity of FMN (a) and compound 4 (b) in BV2 cells 
was assessed by XTT assay. Values correspond to means of 3 independent 
experiments and are shown as the percentage of viable cells compared with the 
viability of negative controls (untreated cells). *p<0.05, **p<0.01, ***p<0.001 in 
comparison with LPS control. #p<0.05, ##p<0.01, ###p<0.001 in comparison with 
untreated cells.   
4.2.3 Effects on nitrite production   
Nitric oxide is an important mediator for the regulation of chronic neuroinflammation. 
Moreover, high concentrations of NO have been shown to be neurotoxic to adjacent 
neurons (Spencer et al., 2012). Therefore, the effects of the compounds at 5, 10, 15 
and 20 µM were investigated for nitrite production in BV2 microglia cells using Griess 
assay.  Figure 33 shows that FMN and compound 4, effectively inhibited NO release 
in a dose-dependent manner (p<0.001).  
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Figure 33. Effect of FMN and compound 4 on nitrite production in LPS-activated 
BV2 microglia. This figure illustrates a reduction in nitric oxide (NO) release in LPS-
a) b) 
a) b) 
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activated BV2 cells after treatment with FMN (a) and compound 4 (b). Data is 
expressed as mean ±SEM for 3 independent experiments. Statistical analysis was 
performed using one-way ANOVA with post-hoc Student Newman-Keuls test (multiple 
comparison). *p<0.05, **p<0.01, ***p<0.001 in comparison with LPS control. #p<0.05, 
##p<0.01, ###p<0.001 in comparison with untreated cells.   
4.2.4 Effects of release of pro-inflammatory cytokines  
Hyperactive microglia are known to release pro-inflammatory cytokines such as IL-1β, 
TNF α and IL-6, which are considered major significant neurotoxic factors that 
contributes to neuroinflammation. Therefore, cytokines production in the activated 
microglia remains an important target in reducing neuroinflammation. The levels of 
IL1β, TNF α and IL-6 in the supernatants were analyzed using ELISA in order to 
assess whether novel compounds were able to prevent the production of these 
important cytokines from LPS-activated BV2 microglia. The following graphs (Figure 
34 and 35), provide an overview of the drugs effect on cytokines. 
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Figure 34. Effect of FMN on TNFα, IL-6 and IL-1β production in LPS-activated 
BV2 microglia. Cells were stimulated with LPS in the presence or absence of FMN 
a) b) 
c) 
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(5-20 μM) for 24 hours. Stimulation was terminated, and supernatants were collected 
and levels of (a) TNF-α, (b) IL-6 and (c) IL-1β were measured using ELISA. Data is 
expressed as mean ±SEM for 3 independent experiments. Statistical analysis was 
performed using one-way ANOVA with post-hoc Student Newman-Keuls test (multiple 
comparison). *p<0.05, **p<0.01, ***p<0.001 in comparison with LPS control. #p<0.05, 
##p<0.01, ###p<0.001 in comparison with untreated cells.   
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Figure 35. Effect of compound 4 on TNFα, IL-6 and IL-1β production in LPS-
activated BV2 microglia. Cells were stimulated with LPS in the presence or absence 
of compound 4 (5-20 μM) for 24 hours. Stimulation was terminated, and supernatants 
were collected and levels of (a) TNF-α, (b) IL-6 and (c) IL-1β were measured using 
ELISA. Data is expressed as mean ±SEM for 3 independent experiments. Statistical 
analysis was performed using one-way ANOVA with post-hoc Student Newman-Keuls 
test (multiple comparison). *p<0.05, **p<0.01, ***p<0.001 in comparison with LPS 
control. #p<0.05, ##p<0.01, ###p<0.001 in comparison with untreated cells.    
Single analysis for FMN and compound 4 revealed that both compounds were 
successful producing a relevant reduction of the cytokines studied. FMN effectively 
a) b) 
c) 
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decreased TNFα (p<0.001), IL-6 (p<0.05) and IL-1β (p<0.05) (Figure 34). Compound 
4 blocked TNFα (p<0.01), IL-6 (p<0.05) and IL-1β (p<0.01) production gradually after 
stimulation (Figure 35).  
4.2.5 Effects of Prostaglandin E2 production   
Prostaglandin E2 is an arachidonic acid derivative released by activated microglia 
through the enzymatic action of COX-2. The effects of the compounds at 5, 10, 15 and 
20 μM on PGE2 were evaluated after 24 h of stimulation on LPS-activated BV2 
microglia. On the graphs below (Figure 36) PGE2 results are plotted for FMN and 
compound 4. Compound 4 specially produced a significant (p<0.001) reduction of 
PGE2 production at 10, 15 and 20 μM although no reduction was observed at 5 μM. 
However, FMN dropped PGE2 release at all concentrations (p<0.01).  
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Figure 36. Effect of FMN and compound 4 on PGE2 production in LPS-activated 
BV2 microglia. Upon treatment with compounds and BV2 cells stimulation with LPS 
(100 ng/ml), supernatants were collected and PGE2 measured by ELISA. FMN (a) and 
compound 4 (b) significantly reduced PGE2 formation. Data is expressed as mean 
±SEM for 3 independent experiments. Statistical analysis was performed using one-
way ANOVA with post-hoc Student Newman-Keuls test (multiple comparison). *p<0.05, 
**p<0.01, ***p<0.001 in comparison with LPS control. #p<0.05, ##p<0.01, ###p<0.001 
in comparison with untreated cells.   
4.3 DISCUSSION  
Neuroinflammation is a critical component of a broad array of neurodegenerative 
diseases. Moreover, increasing evidence suggests that chronically hyperactivated 
microglia cells are mainly responsible for the exacerbation and maintenance of this 
a) a) 
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condition. To date, the majority of drug treatments are addressed to treat the 
symptoms of the neurodegenerative disorders rather than preventing the underlying 
degeneration of neurons. Accordingly, there is a need and desire to develop novel 
therapies capable of preventing neuronal loss that trigger pathology in these diseases 
(Spencer et al., 2012).  In this project, neuroinflammation inhibitory actions of the 
dietary isoflavonoid FMN, highly present in red clover and compound 4, a carbamate 
ester of FMN, were investigated in LPS-activated BV2 microglia.  
Microglia stimulation with bacterial LPS derived from Salmonella typhimurium resulted 
in an increase in the production of pro-inflammatory cytokines like TNFα, IL-1β and IL-
6 and other inflammatory modulators such as nitric oxide. Nitric oxide is released by 
the iNOS and levels of both of them should be interrelated. Activated microglia also 
produced PGE2 whose production is controlled by COX-2 enzyme (see chapter 1 and 
3).   
The present study and other unpublished studies from our group confirm FMN’s 
suppressive capability on BV2 cells inflammatory response. FMN effectively reduces 
the production of pro-inflammatory modulators NO (p<0.001), TNFα (p<0.001), IL-6 
(p<0.05), IL-1β (p<0.05) and PGE2 (p<0.01) in a dose-dependent manner in LPS-
activated BV2 microglia, suggesting that the compound is capable of inhibiting 
neuroinflammation. These results confirm other reports in which FMN is tested for its 
anti-inflammatory properties (Wang et al., 2012; Ma et al., 2013).   
Compound 4 exhibited the same anti-inflammatory pattern than that of FMN by also 
decreasing the production of pro-inflammatory modulators NO (p<0.001), TNFα 
(p<0.01), IL-6 (p<0.05), IL-1β (p<0.01) and PGE2 (p<0.001) in a dose-dependent 
manner suggesting that compound 4 is a bioactive derivative. It would be interesting 
to perform IC50 assays for this compound for comparison with FMN in order to know 
whether the addition of a lipophilicity group using the formation of a carbamate ester 
is a good strategy as a prodrug.   
The actions of isoflavones and their metabolites are predominantly mediated by the 
ERs (ERα and ERβ), which differ in tissue distribution. While ERα is mainly found in 
the adrenals, the kidney, and the testes, typical ERβ-rich tissues are the brain, the 
thymus, the prostate, the bladder, the bone, the lungs, and the vasculature. In the 
breast, the ovaries and the uterus, both ERs are found. In relative binding affinities for  
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ERα and ERβ experiments, FMN (along with other isoflavones such as BCA) 
demonstrated 15,000 times less potency than 17 β-estradiol (Wang et al., 1995). The 
affinity assays performed for FMN have revealed higher affinity towards ERβ than to 
ERα just like other isoflavones. Moreover, daidzein, the demethylated metabolite of 
FMN, increases receptor affinity. In addition, their metabolite equol possess even 
greater affinity and potency than either of them (Pfitscher et al., 2008).  
Despite the promising health benefits mentioned above that FMN might possess, it 
needs to be taken in consideration the possible carcinogenesis activity of isoflavones 
like FMN. Contrary to other reports (Wu et al., 2017; Chen et al., 2016) that showed 
anti-proliferation and lower invasiveness capacity of FMN in carcinogenic bladder cells 
and arrest of abnormal proliferation and migration of vascular smooth muscle cells 
respectively, several authors like Wang et al. (1995) demonstrated an ability of FMN 
to support mammary gland proliferation in mice and, Guo et al., (2016) concluded that 
FMN stimulates CNE2, a nasopharyngeal carcinoma cell line, proliferation and has an 
inhibitory effect on apoptosis.   
On the other hand, it must be beard in mind that FMN is finally metabolized in the 
organism to equol, which has showed higher receptor transactivation than daidzein 
and FMN (Pfitscher et al., 2008), concluding that possible beneficial health effects of 
isoflavone-rich foods and food supplements may be attributed to this secondary 
metabolite.   
Taken together, results on FMN experiments suggest that it may inhibit 
neuroinflammation in BV2 microglia. On the other hand, the addition of an alkyl chain 
with a carbamate group resulted in compound 4 having similar anti-inflammatory 
properties on BV2 cells. Further investigation on molecular studies, ligand binding 
assays, IC50 evaluation, transactivation and bioavailability assays could shed some 
light in determining whether the chemical modification conducted would be beneficial 
to enhance FMN pharmacological properties.  
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CHAPTER 5: DISCUSSION AND CONCLUSIONS  
There is no doubt that estrogens have a fundamental role in the development and 
functioning of various organs and tissues in the body, including, but not limited to, 
brain, bone, the cardiovascular system, and tissues of the urogenital tract.   
Since the discovery of diverse ERs subsets is relatively recent, there is still a long way 
to go in the understanding of the functioning of the subtypes identified hitherto. 
Therefore, the concrete study of the existing and newer ER subtype–selective agonists 
is vital for deciphering their specific roles in health and disease.  
Among the ERs subtypes, therapies targeting ERβ seems to be a safer strategy than 
targeting ERα because this receptor has been associated with enhanced proliferation 
features in breast and utter tissues (Lin et al., 2007; Montanaro et al., 2005). Also, for 
cancers like prostate cancers and breast cancer ERβ-selective agonists may become 
the therapy of choice. Despite this apparent drawback, it is worth highlighting that 
several ERα seems to play a major role in targeting neurodegenerative diseases such 
as AD and PD. Bearing this in mind, the development of SERMs would be the most 
logical and rational strategy when it comes to decide on the synthesis strategy used 
(Elzer et al., 2010). Another strategy would be to use the so-called non-feminizing 
compounds, which having estrogen-like structures do not bind to or exert a weaker 
effect on ERs. For example, ZYC-3, an estrogen analogue with no binding affinity for 
either ERα or ERβ, was 10-fold more potent than 17β–E2 against glutamate-induced 
cytotoxicity (Liu et al., 2002) suggesting a strong capability as a neuroprotective agent.  
Numerous in vitro and in vivo studies suggest that isoflavones have the potential to 
exert neuroprotective effects by suppressing microglial cells activation, and thus, 
cytokine release and nitric oxide/superoxide production (Valles et al., 2010; Ong et al., 
2017). Such activity may be due to the structural homology between human natural 
occurring estrogen and isoflavones, which display binding affinity for estrogen 
receptors, in particular towards ERβ which is expressed in glial cells (Spencer et al., 
2012). Although, the biological activity of phytoestrogens differs and is frequently 
described as less active than mammal or synthetic estrogens (Ososki and Kennelly, 
2003).  
Besides in vitro and in vivo experiments, molecular docking studies have also 
confirmed that flavonoids and isoflavonoids identified in red clover (Trifolium pratense), 
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have ERα and ERβ binding activity showing a binding preference for ERβ (Powers and 
Setzer, 2015).   
Differences in estrogenic activity of similarly classified chemicals may be due to the 
structural features or deviations in those structures (Ososki and Kennelly, 2003). To 
account for the results reported, certain features in terms of ligand-receptor 
interactions and metabolism are to be taken into consideration.   
It is known that ligand binding to ERα and ERβ depends on a unique combination of 
structural characteristics starting for two hydroxyl groups (-OH) with a distance 
between them similar to that of the estradiol’s (10.8 Å) (Ososki and Kennelly, 2003; 
Fokialakis et al, 2004). The planarity ring system and a suitable electron density on 
the ring A are also factors to take in consideration. Taking as an example the 
extensively studied isoflavone genistein, their OH in the fourth carbon (4’-OH) and in 
the seventh (7-OH) are known to mimic those of the estradiol in position 3 and 17. 
However, both H bond formations may not be possible for BCA and FMN due to the 
methylation of its 4’-OH (Fokialakis et al., 2012).   
As remarked in previous chapters, neurotoxivity related to neuroinflammation 
contributes to the development of neurodegenerative diseases like AD, PD and ALS. 
In addition, pro-inflammatory mediators such as TNFα, IL-1β and IL-6 released by 
activated microglia are shown to induce damage to adjacent neurons. Theoretically, 
compounds that are able to inhibit the production of pro-inflammatory cytokines would 
be expected to confer protection against neurotoxicity.  
The present work is a preliminary study of novel plant-derived compounds, which aims 
to pave the way for a further and deeper study on how phytoestrogen inhibit 
neuroinflammation. Two carbamate ester (compound 1 and 4), an ester (compound 2) 
and a deoxybenzoin intermediate, derivatives from BCA and FMN have been 
synthesized in this study. Results show that derivatives of the isoflavonoids BCA and 
FMN may possess anti-inflammatory properties, as well as minor changes in their 
structure can lead to the opposite effect.   
Esterification of hydroxyl group(s) and the use of carbamate esters have been two of 
the preferred prodrug strategies over the years. Moreover, branched acyl group shows 
higher lipophilicity and slower chemical or enzymatic hydrolysis. (Férriz et al., 2010). 
We have followed these approaches in order to make novel derivatives of BCA and 
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FMN. Logically, these new compounds should display higher pharmacological 
efficiency.  
BCA is an ER-β selective isoflavone mostly found in Trifolim pratense (family 
Fabeaceae) that has been shown to effectively suppress LPS-stimulated 
overproduction of cytokines and certain transcriptional factors by inhibiting the 
activation of the MAPK pathway in BV2 cells (Wang-Yang et al., 2014; Zhang et al., 
2015; Wang et al., 2016). The present study confirms that BCA inhibits the production 
of TNFα, IL-1β and IL-6 in BV2 microglia stimulated with LPS. BCA effectively reduces 
the production of TNF-α and IL-1β in LPS-activated BV2 microglia, suggesting that the 
compound is capable of inhibiting neuroinflammation. However, it did not significantly 
suppress IL-6 release. Such results contrast other previous studies in which IL-6 had 
been evaluated after treatment with BCA in primary microglial cells. In this latest study, 
BCA effectively decreases IL-6 along with the other CKs (Wang et al., 2016). After 
stimulation with LPS, BV2 cells were shown to increase the production of nitric oxide 
and PGE2. Upon treatment with BCA, both inflammatory modulators, NO and PGE2 
decreased.  
Compound 1 was synthesized as described by Fokialakis et al. (2012) from BCA and 
we show for the first time its anti-inflammatory effects, however, the mechanism by 
which it acts has not been elucidated yet. In an attempt to clarify such pharmacological 
activity, the main pro-inflammatories CKs were evaluated, overall, all CKs were 
significantly reduced. Compound 1 also inhibited neuroinflammation by blocking iNOS 
protein expression and nitric oxide production in the microglia. In addition, it reduced 
the expression of COX-2 and its mediated PGE2 production in LPS stimulated 
microglia specially at the dose of 15 µM, suggesting that compound 1 possesses 
neuroinflammation inhibitory activities. Previously, compound 1 was reported to 
display ten times weaker affinity to ERs than compound BCA (Fokialakis et al., 2012) 
from which it could be deduced that compound 1 would have lower pharmacological 
efficacy than BCA. However, conclusions must be carefully taken since, for instance, 
Pfitscher and co-workers (2008) describe a metabolite (angolensin) that had lower 
binding affinities to both ERs but comparable transactivation potential to equol, a 
daidzein metabolite (see Chapter 3) indicating that angolensin would be implicating in 
other type of molecular mechanisms.  
In contrast, compound 2, also a BCA derivative, has been synthesized from scratch 
causing, surprisingly, opposite effects by increasing pro-inflammatory CKs and yet 
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decreasing NO release. From our knowledge, there are no references for compound 
2 to be compared with. However, many authors have studied similar compounds and 
structures on the basis of the ER ligand cavity diversity (Chakrabarti et al., 2014; 
Powers and Setzer, 2015). Regarding the atypical activity of compound 2, it might be 
related not only to the structure itself but also to the concentration used. Some authors 
have described several isoflavones and their metabolites with a dual activity, acting as 
an estrogenic agonist or antagonist depending on the estrogen concentration (Ong et 
al., 2017; Hwang CS et al, 2006). PGE2 production also augmented significantly 
(p<0.01). Steroids and non-steroids anti-inflammatory drugs are expected to drop 
PGE2 production. However, their effects are reliant on the complex and yet not 
completely understood regulation of this mediator (Kalinski, 2012). Bearing in mind the 
importance of the structural characteristics stated above, besides other hydrophobic 
and hydrophilic interactions, and despite the in vivo evidences on phytoestrogen 
triggering neuroinflammation, it is striking that compound 2 displays the opposite 
action by increasing the cytokine release in a dose-dependent manner. Even though 
the mechanism by which this occurs still needs to be elucidated, it is likely that such 
antagonist action is due to the lack of the possibility of a hydrogen binding between 
the ester and the ER itself. Unlike compound 1 and 4, which have a carbamate group 
and therefore, an –NH capable of forming a hydrogen binding with the ER, compound 
2 contains a long carbon chain joined by an ester (-COO-) which does not possess a 
free hydrogen to interact within the receptor. Such slightly differences between BCA 
and its derivatives could illustrate the importance of H bond formation between the 7-
OH group and the receptor. In fact, Fokialis et al. (2012) obtained lower affinities 
binding to ERs for their novel BCA derivatives rather than for BCA evidencing the 
inability of this binding.  
As for compound 3, the Biochanin deoxybenzoid, was proved to be cytotoxic for BV2 
cells as the dose used increased. Fokialakis et al. (2004) also synthesized this 
compound and observed that its higher affinity was bias the ERα subtype.    
FMN is an isoflavone found in red clover plant and widespread in the Leguminosae 
family that has been reported to possess many health benefits. In the present project 
FMN was synthesized in order to develop a carbamate ester derivate named 
compound 4. We demonstrate that both compounds are bioactive in BV2 cells showing 
possible neuroprotective abilities.   
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Overall and despite the nature of the compounds studied, the results suggest that only 
compound 1 and 4 and their scaffold structures exhibited inhibition of 
neuroinflammation in LPS-activated BV2 microglia.  
In the light of the observed effects on pro-inflammatory mediators, there is a need for 
further investigation of the mechanism(s) of action of these compounds. Further 
investigation is needed to reveal the structural-activity relationship that is required for 
a natural product to be active as a phytoestrogen. To do so, we would suggest to 
synthesize more compounds with the same isoflavone scaffold but modifying the 
length of the side chain. As for the pharmacology experiments, immunofluorescence 
along with ligand-binding assays would shed some light on whether all compounds are 
interacting with ERs or, on the contrary, their effect is due to the interaction with other 
type of receptors. Moreover, IC50 experiments would determine the effectiveness of 
the compounds synthesized against the natural compounds. It is evident that BBB 
represents a major obstacle for the compounds to enter CNS. Therefore, it is crucial 
to investigate the capability of all these compounds to cross BBB using in vitro models 
such as Human Brain Endothelial Cell Line (HCMEC/D3) cell line. 
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ANNEX I: ADDITIONAL MATERIAL 
 
 
 
Mass Spectrometry Data Summary: 
Observed m/z Most likely adduct 
Observed 
neutral mass 
Theoretical 
neutral mass 
Certainty 
score / 100 
Mass diff. 
/ ppm 
482.2523 [M+H]+ 481.2450 481.2464 94.07 3.02 
985.4821 [2M+Na]+ - - - - 
 
Expected Mass for [C28H35NO6+?]+: 
 
Spectrum I.D results (optimised) 482.2523m/z: 
 
 
Conclusion: 
 
BCA Undecyl Isocyanate S observed as the [M+H]+ & [2M+Na]+ adducts corresponding 
to the desired compound (94%) with a relative mass difference of 3.02 ppm. 
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Mass spectrum:  
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Mass Spectrometry Data Summary: 
Observed m/z Most likely adduct 
Observed 
neutral mass 
Theoretical 
neutral mass 
Certainty 
score / 100 
Mass diff. 
/ ppm 
467.2414 [M+H]+ 466.2342 466.2355 92.74 2.95 
594.2833 [M+Na]+ - - - - 
955.4597 [2M+Na]+ - - - - 
 
Expected Mass for [C28H35NO6+?]+: 
 
Spectrum I.D results (optimised) 467.2414m/z: 
 
 
594.2833m/z: 
 
 
Conclusion: 
BCA Dodecanoic Ester observed as the [M+H]+ & [2M+Na]+ adducts corresponding 
to the desired compound (93%) with a relative mass difference of 2.95 ppm. One 
significant impurity observed, with MS data strongly suggesting a formula of 
C34H41O9. 
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Mass spectrum:  
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Mass Spectrometry Data Summary: 
Observed m/z Most likely adduct 
Observed 
neutral mass 
Theoretical 
neutral mass 
Certainty 
score / 100 
Mass diff. 
/ ppm 
269.0808 [M+H]+ 268.0735 268.0736 97.14 0.33 
291.0626 [M+Na]+ 268.0734 268.0736 96.71 0.68 
559.1349 [2M+Na]+ - - - - 
 
Expected Mass for [C16H12O4+?]+: 
 
Spectrum I.D results 269.0808m/z: 
 
 
291.0626m/z: 
 
Conclusion: 
FMN was observed as the [M+H]+ & [M+Na]+ adducts corresponding to the desired 
compound (97%) with a relative mass difference of 0.33 ppm. 
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Mass spectrum:  
  
118  
  
 
 
ANNEX II: BUFFERS PREPARATION  
1. GELS COMPOSITION FOR WESTERN BLOT  
  
Stacking gel (5% of acrylamide)  
Acrylamide solution/bis-acrylamide 30% w/v                       330 µl  
 1M Tris HCl pH 6.8                                                               250 µl  
  SDS 10%                                                                               20 µl     
Amonium persulphate to 10%                                                 20 µl     
TEMED                                                                                      2 µl     
Water miliqoure (q.s.)                                                                2 ml    
  
Running gel (10% of acrylamide)  
          Acrylamide solution/bis-acrylamide 30% w/v  3.3 ml  
          1M Tris Base pH 8.3  2.5 ml  
          SDS 10%  100 µl  
          Amonium persulphate to 10%  100 µl  
          TEMED      4 µl  
          Water miliqoure (q.s.)      10 ml  
  
  
2. BUFFERS PREPARATION FOR WESTERN BLOT  
  
Running Buffer 10X 
    Tris Base 30.3 g 
    Glycine 144.0 g 
     SDS 10.0 g 
     Distilled water (q.s.) 1 L 
 
 
  
Transfer Buffer 10X 
     Tris Base 30.3 g 
     Glycine 144.0 g 
     Distilled water (q.s.) 1 L 
      Add 20% of methanol to prepare Transfer Buffer 1X 
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